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    จากผลการศึกษาน้ี สามารถสรุปไดว้า่ ออกซาซิลลิน มีฤทธ์ิตา้นเช้ือโออาร์เอสเอสนอ้ยมาก 
ในขณะท่ีสารสกดัจากเปลือกผลมงัคุดเหล่าน้ี มีความแรงสูงกวา่ยาเม่ือใชเ้ด่ียวๆน้ีมาก ยิ่งไปกวา่นั้น
ส่วนผสมของสารสกดัเหล่าน้ี โดยเฉพาะแอลฟา-แมงโกสตินและออกซาซิลลิน แสดงฤทธ์ิเสริมกนั
ในการตา้นเช้ือน้ีอยา่งชดัเจน ดงันั้น การคน้พบน้ี เป็นเคร่ืองพิสูจน์วา่ สารสกดัจากเปลือกผลมงัคุด
เหล่าน้ี ออกฤทธ์ิเสริมกบัออกซาซิลลินเพื่อใหอ้อกซาซิลลินสามารถน ากลบัมาใชใ้หม่กบัเช้ือท่ีด้ือต่อ
ยาตวัน้ีแลว้        
 กล่าวโดยสรุป การเสริมฤทธ์ิท่ีเกิดข้ึน อาจมาจากกลไกการยบัย ั้งการสังเคราะห์ผนงัเซลล ์
หรือการลดการซึมผ่านของเยื่อหุ้มเซลล์ชั้นนอกและชั้นใน สารสกดัจากเปลือกผลมงัคุดเหล่าน้ีมี
ความปลอดภยัสูงส าหรับการรักษา ดว้ยเหตุน้ี อาจสามารถพฒันาสารเหล่าน้ี โดยน ามาผสมกบัออก
ซาซิลลินในการต้านเช้ือโออาร์เอสเอส ซ่ึงในปัจจุบนัด้ือต่อยาในกลุ่มเพนนิซิลลินแทบทุกตัว       
การทดสอบน้ี ยงัคงตอ้งทดสอบในสัตวท์ดลองและในมนุษยต่์อไป  
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GARCINIA  MANGOSTANA  L./β-LACTAM ANTIBIOTICS/ANTIBACTERIAL 
ACTIVITY/STAPHYLOCOCUS SAPROPHYTICUS 
 
In the recent years, incidence of multidrug resistance in pathogenic and 
opportunistic bacteria has been increasingly documented. The search for novel 
antibacterial agents that can reverse the resistance to β-lactam antibiotics are research 
objectives of far reaching importance and urgently needed. Thus, the objective of this 
study was to investigate the activity of bioactive compounds from the pericarp extract 
of Garcinia mangostana L. (GML) against drug resistant bacteria, when use alone and 
in combination with β-lactams antibiotic. The mature GML fruits extraction and 
identification methods were accomplished. The CH2Cl2 crude extract, Fr3 extract, and 
α-mangostin were extracted by Soxhlet extraction. Main compound structure is 
identified as -mangostin using NMR. MIC values of CH2Cl2 crude extract, Fr3 
extract, α-mangostin, and oxacillin against oxacillin-resistant S. saprophyticus (ORSS) 
revealed 50, 31, 8, and 128 µg/mL, respectively. However, the MIC values of GML 
extracts either alone or in combination with oxacillin exhibited high resistant against 
both ceftazidime-resistant E. coli and ceftazidime-resistant E. cloacae strains in all 
treated compounds. So that, these results indicate that these compounds revealed a 
higher potency against ORSS than oxacillin alone. The checkerboard displayed that the 
FICs index of CH2Cl2 crude extract, Fr3 and α-mangostin plus oxacillin revealed 
 
 
 
 
 
 
 
 
 
IV 
synergistic effects at 0.25, 0.138, and 0.375 respectively against ORSS strain. The 
killing curves proved that the combination of these extracts plus oxacillin caused a 
marked decrease of ORSS cells within 6 h and throughout 24 h period. The TEM 
method exhibited that the effect of the combination of oxacillin plus these compounds 
at sub-MIC value on ORSS revealed great deal smaller than the control cells, cell 
shape distortion and cell envelope damage in most of these cells. In addition, either 
compound alone or in combination with oxacillin at sub MIC value steady increased 
the OM and CM permeability of this strain. Besides, the SDS-PAGE results exhibited 
that there was an absence of protein bands at higher MW whereas appeared darker at 
lower MW of these compounds treated cells compared to control.  
     From these results, it can be concluded that GML compounds showed rather 
higher potency than oxacillin alone against this strain. Moreover, the combination of 
oxacillin and these compounds, especially -mangostin, obviously showed great 
synergism activity against this strain. So, our findings provide evidence that these 
compounds have the synergistic effect with oxacillin to reverse bacterial resistance to 
oxacillin against this resistant strain.  
     To conclude, this activity may be involved two mechanisms of action, 
including the cell wall synthesis inhibition and steady increase OM and CM 
permeabilization. These compounds have a sufficient margin of safety for therapeutic 
use.  For this reason, these compounds offer for the development of a valuable adjunct 
to oxacillin against ORSS, which currently almost penicillins resistance. These in vitro 
results have to be still confirmed in an animal or in humans test.  
School of Biology Student’s Signature___________________ 
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CHAPTER I 
INTRODUCTION 
 
1.1 Introduction 
 Multidrug resistance in pathogenic bacteria at an alarming rate increase. Thus, 
the search for new antibiotics and new approaches to treat these bacterial infections 
are urgently needed. In recent years, incidence of multidrug resistance in pathogenic 
and opportunistic bacteria has been increasingly documented (Jones et al., 2004). 
These multidrug resistant bacteria have also created immense clinical problems in 
immune compromised patients. Most important multidrug-resistant   bacteria on the 
global scale include Gram-positive (methicillin-resistant Staphylococcus aureus, 
vancomycin resistant enterococci) and Gram-negative bacteria (members of 
enterobacteriaceae producing plasmid mediated extended spectrum β-lactamase 
(ESβL)) and others like Pseudomonas aeruginosa, Mycobacterium tuberculosis 
(Medeiros, 1997; Sajduda et al., 1998).  Around 90-95% of Staphylococcus aureus 
strains worldwide are resistant to penicillin (Casal et al., 2005) and in most of the 
Asian countries, 70-80% of the same strains are methicillin-resistant (Chambers, 
2001). Staphylococcal resistance  to wide spectrum of β-lactam antibiotics, such as  
methicillin, oxacillin and flucloxacillin, emerged soon after the introduction of the 
first drug in this class and  there has been a steady rise in the incidence of methicillin  
resistant S. aureus (MRSA) clinical isolates (Bush, 2004). Staphylococci show a 
strong tendency to accumulate antibiotic-resistant genes and the majority of MRSA
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isolates are now resistant to a range of antibiotics (Firth, 2003). Reports on 
vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus 
aureus (MRSA) infections in hospitals have increased worldwide in recent years 
(Emori and Gaynes, 1993; Leclercq and Courvalin, 1997; Moellering, 1998; Murry, 
1997). There are a considerable number of reports on valuable trials carried out to 
control the infections caused by VRE (Garner, 1996; Montecalvo et al., 1999a; 
Nourse et al., 2000; Slaughter et al., 1996) and MRSA (Cookson, 1995; Cox et al., 
1995; Kotilainen et al., 2001; Voss et al., 1994). Strains of ceftazidime-resistant 
Escherichia coli (CREsC), ceftazidime-resistant Enterobacter cloacae (CREnC) 
including β-lactam-resistant Staphylococcus aureus and methicillin-resistant S. aureus 
(MRSA) have been posing serious problems to hospitalized patients and their care 
providers (Liu et al., 2000; Maharat Nakhon Ratchasima hospital, 2012; Mulligan et 
al., 1993).   
 MRSA are the most common organisms causing infections of the urinary tract, 
surgical wounds, skin respiratory and gastrointestinal tract including Escherichia coli 
and Enterobacter spp. (Isogai et al., 2001; Sundaram et al., 1983; Wang et al., 2003). 
In addition, antibiotics are sometimes associated with adverse effects on the host, 
which include depletion of beneficial gut and mucosal microorganisms, 
immunosuppression, hypersensitivity and allergic reaction. The drugs-resistant 
bacteria have further complicated the treatment of infectious diseases in 
immonocompromised, AIDS and cancer patients, especially in the case of nosocomial 
infections (McGaw et al., 2000). There is not only the loss of an effective antibiotic 
against multidrugs-resistant bacteria, but also a global problem for the loss of budget 
for treatment of infectious diseases.   
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 Plant-derived antibacterials are an interesting source of novel therapeutics. For 
example, an  active ingredient called galangin which was synergism with penicillin 
for MRSA inhibition (Eumkeb et al., 2010) 
 Many plants have interesting biological activities with potential therapeutic 
applications. Mangosteen (Garcinia mangostana Linn.) (GML), belonging to the 
family Guttiferae, is a tropical evergreen tree. Its origin is in Southeast Asia, India, 
Myanmar, Malaysia, Philippines, Sri Lanka, and Thailand. (Morton, 1987). GML 
(Figure 1.1A) is commonly known as Mang Kut, and is referred to as ‘‘the queen of 
fruits’’ in Thailand, which is very popular due to its delicious taste. The pericarp, 6–
10 mm in thickness, dark purple or reddish (Figure 1.1B), has been used as a 
traditional medicine in Southeast Asia for the treatment of diarrhea, inflammation, 
and ulcers (Farnsworth and Bunyapraphatsara, 1992; Peres et al., 2000; Suksamrarn et 
al., 2006).  Mangosteen fruit is a rich source of phenolic compounds such as 
xanthones, condensed tannins and anthocyanins (Fu et al., 2007; Jung et al., 2006; 
Mahabusarakam et al., 1987).  
 Xanthone derivatives, as the major secondary metabolites of G. mangostana 
fruits (Ji et al., 2007; Mahabusarakam et al., 1987), exhibited antibacterial (Sakagami 
et al., 2005; Suksamarn et al., 2003), antifungal (Gopalakrishnan et al., 1997), anti-
inflammatory (Nakatani et al., 2004), antioxidant (Jung et al., 2006; Yu et al., 2007), 
antiplasmodial (Mahabusarakam et al., 2006), and cytotoxic activities (Matsumoto et 
al., 2005; Suksamrarn et al., 2006).  
 The xanthones, α- and γ-mangostin, are major bioactive compounds found in 
the pericarp of the mangosteen (Figure 1.1C) (Chairungsrilerd et al., 1996a, b, c ; 
Jinsart et al., 1992). The biological activities of α-mangostin have been confirmed to 
 
 
 
 
 
 
 
 
4 
 
consist of a competitive antagonism of the histamine H1 receptor (Chairungsrilerd  et 
al., 1996a; Iikubo et al., 2002), antibacterial activity against Helicobacter pylori, anti-
inflammatory activities, inhibition of oxidative damage by human low-density 
lipoproteins (LDL) (Iikubo et al., 2002), antimicrobial activity against methicillin-
resistant Staphylococcus aureus (Chomnawang et al., 2009; Iinuma et al., 1996), 
weak antioxidant activity (Chairungsrilerd  et al., 1996a), and inhibition of alveolar 
duct formation in a mouse mammary organ culture model and suppression of the 
carcinogen induced formation of aberrant crypt foci in a short-term colon 
carcinogenesis model (Jung et al., 2006; Nabandith et al., 2004).  The other xanthone 
derivative, γ-mangostin has also been reported to have several pharmacological 
activities, such as being a potent inhibitor of animal Cdk activating  kinases (Cak), 
plant Ca
2+
-dependent protein  kinases (CDPK) (Jinsart et al., 1992), and a selective 
antagonist for 5-HT2A receptors in smooth muscle cells and platelets  
(Chairungsrilerd et al., 1996b, 1998). Moreover, α- and γ-mangostin can inhibit both 
human immunodeficiency virus (HIV) infection (Chen et al., 1996; Vlietinck et al., 
1998), and topoisomerases I and II (Tosa et al., 1997).  
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Figure 1.1 The Garcinia mangostana L. tree (A), the appearance of mangosteen fruit 
(B), and the chemical structures of xanthones included in the pericarps 
(C). 
Source: Akao et al. (2008). 
 
 Maharat Nakhon Ratchasima hospital is the largest hospital in Nakhon 
Ratchasima province, northeast of Thailand. The problems of drug-resistant bacteria 
are found in high level in many sections of this hospital and other hospitals in 
 
(A) (B) 
(C) 
Garcinia mangostana L. 
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Thailand and worldwide (Jungthirpanich et al., 2000; Kusum and Dejsirilert, 2003; 
Maharat Nakhon Ratchasima hospital, 2012). 
 However, no works have investigated the effect of GML extract on some drug 
resistant bacteria such as Staphylococcus saprophyticus (S. saprophyticus), 
Enterobacter cloacae (E. cloacae), and Escherichia coli (E. coli). The purpose of this 
thesis was to investigate the activity of bioactive compound from the pericarp extract 
of Garcinia mangostana against drug resistant bacteria, when used alone and in 
combination with β-lactam antibiotics. Thus, the development of a new class of 
antibacterial agent may be developed.   
 
1.2 Research objectives 
 (1) To test the effectiveness of α-mangostin or other bioactive compounds from 
the pericarp of GML extract on drug resistant bacteria when use alone.  
 (2) To test the effectiveness of α-mangostin or other bioactive compounds from 
the pericarp of GML extract on drug resistant bacteria in combination with 
antibacterial drugs. 
 (3) To investigate the elementary mechanism of action of α-mangostin or other 
bioactive compounds from the pericarp of GML extract on drug resistant bacteria 
when used alone or in combination with antibiotic drugs by examining morphology 
with transmission electronmicroscopy (TEM), outer and cytoplasmic membrane 
permeability and electrophoresis methods. 
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1.3 Research hypothesis 
  (1) α-Mangostin or other bioactive compounds from the pericarp of GML 
extract on drug resistant bacteria can show antibacterial activity against drug resistant 
bacteria. 
 (2) α-Mangostin or other bioactive compounds from the pericarp of GML 
extract on drug resistant bacteria in combination with antibiotic drugs can show 
synergistic activity against drug resistant bacteria. 
 
1.4 Scope and limitation of the study 
 (1) The mangosteen fruits (Garcinia mangostana L.) were purchased from a 
local market in Nakhon Ratchasima, Thailand. The pericarps of mangosteen fruits 
were extracted and α-mangostin or other bioactive compounds were isolated with a 
little modification method.   
 (2) Clinical isolates of Staphylococcus saprophyticus (S. saprophyticus), clinical 
isolates of Enterobacter cloacae (E. cloacae) and clinical isolates of Escherichia coli 
(E. coli) were obtained from Department of Medical Science, National Institute of 
Health, Ministry of Public Health, Thailand and the American Type Culture 
Collection (ATCC), USA. 
 (3) Oxacillin and ceftazidime were obtained from Sigma, Bristol-Myers. 
 (4) Checkerboard assay of combinations that showed the lowest MIC were 
selected for further investigations such as viability counts, transmission 
electronmicroscopy (TEM), outer and cytoplasmic membrane permeability and 
electrophoresis methods. 
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1.5 Expected results 
 (1) Additional scientific data on synergism antimicrobial activity of the 
combination of oxacillin and α-mangostin or other bioactive compounds from the 
pericarp of GML extract and antibiotic drugs on drug-resistant bacteria will be 
obtained. 
 (2) Novel knowledge for further investigations such as mechanism of action of 
α-mangostin or other bioactive compounds from the pericarp of GML extract on drug 
resistant bacteria in animals and human will be known. 
 (3) The results may be useful for the development of new drug combination 
against drug-resistant bacteria.  
 (4) The results of the study will be a benefit to physicians and patients in case of 
tackling most of the dangerous drug-resistant bacteria by using new antibacterial 
combination drugs. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Overview of mangosteen 
 Mangosteen (Garcinia mangostana L.) is classified in family Guttiferae, genus 
Garcinia and Thai people call mangosteen as Mang Kut (Smitinand, 2001). 
Mangosteen is one of praised tropical fruits. This kind of fruit is usually eaten as 
dessert. Furthermore, they can be made as processed products such as juice, jam, jelly 
and sugar. The seeds are sometimes eaten alone after boiling or roasting (Figure 1B). 
   2.1.1 Pericarp active ingredients and their pharmacological data 
                   Asai et al. (1995) reported that chemical constituents in pericarp of 
mangosteen consisted of xanthone derivatives such as alpha-mangostin, beta-
mangostin, gamma-mangostin, gartanin, garcinone E, 1,5-dihydroxy-2-(3-methylbut-
2-enyl)-3-methoxy, 1,7-dihydroxy-2-(3-methylbut-2-enyl)-3-methoxyxanthone and 
mangostinone (Figure 1.1C). 
 Chairungsrilerd et al. (1996a) described that the fruit hull (pericarp) of 
mangosteen was used as an anti-inflammatory agent, astringent and in the treatment 
of diarrhea. They reported that the yellowish excretion of the fruit hull, alpha-
mangostin, gamma-mangostin and mangostanol, showed an inhibitory effect on 
cAMP phosphodiesterase. 
 Moreover, extracts of the pericarp of fruit have been used as                            
a traditional medicine in Thailand for the treatment of trauma, diarrhea, and skin 
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infections (Nakatani et al., 2002). The biological activities of α-mangostin have been 
confirmed to consist of a competitive antagonism of the histamine H1 receptor 
(Chairungsrilerd et al., 1996a; Iikubo et al., 2002), antibacterial activity against 
Helicobacter pylori, anti-inflammatory activities, inhibition of oxidative damage by 
human low-density lipoproteins (LDL) (Iikubo et al., 2002), antimicrobial activity 
against methicillin-resistant Staphylococcus aureus (Chomnawang et al., 2009; 
Iinuma et al., 1996), and weak antioxidant activity (Chairungsrilerd et al., 1996a).    
In addition, α- and γ-mangostin can inhibit both human immunodeficiency virus 
(HIV) infection (Chen et al., 1996; Vlietinck et al., 1998), and topoisomerases I and II 
(Tosa et al., 1997). The mangosteen has long been widely used as an anti-
inflammatory, anti-diarrhea, and anti-ulcer agent in Southeast Asia (Harbborne and 
Baxter, 1993; Lu et al., 1998). 
 2.1.2 Current use and importance of α-mangostin    
              α-Mangostin, the first xanthone isolated from mangosteen fruit (Schmid, 
1855), is a yellow coloring matter that can also be obtained from bark and dried sap of 
Garcinia mangostana. In fact, for a long time people in many countries have used the 
pericarp (peel, rind, hull or ripe) of Garcinia mangostana as a traditional medicine  
for the treatment of abdominal pain, diarrhea, dysentery, infected wound, supporation 
and chronic ulcer (Chopra et al., 1956; Pedraza-Chaverri et al., 2008).  Several 
properties have been reported for α-mangostin. For instance, Williams et al. (1995) 
found that α-mangostin decreased the human low-density lipoprotein (LDL) oxidation 
induced by copper or peroxyl radical. Besides, Mahabusarakam et al. (2000) found that 
α-mangostin prevented the decrease in α-tocopherol consumption induced by LDL 
oxidation. As well as, Jung et al. (2006) exhibited that several xanthones isolated from 
 
 
 
 
 
 
 
 
11 
 
the pericarp of Garcinia mangostana, including α-mangostin, were able to scavenge 
peroxynitrite anion. In addition, Suksamrarn  et al. (2003) revealed that   xanthones, 
isolated from the fruit hulls, the edible arils and seeds of Garcinia mangostana, such 
as alpha- and beta-mangostin and garcinone B exhibited strong inhibitory effect 
against Mycobacterium tuberculosis (TB). In the same way, Lin et al. (1996) 
demonstrated that xanthone derived compounds had potent antitumor activities 
against human cancer cells and some of them possessed strong anti-inflammatory 
properties. What is more, Iinuma  et al. (1996) displayed that extracts of fruit of 
Garcinia mangostana, possessed inhibitory effects against the growth of S. aureus. 
So, the strong in-vitro antibacterial activity of xanthone derivatives against both 
methicillin-resistant and methicillin-sensitive Staphylococcus aureus suggested that 
the compounds might find wide pharmaceutical use. Apart from this, Chomnawang  et 
al. (2005) indicated that the active compounds in Garcinia mangostana could be 
mangostin, a xanthone derivative, which had a strong inhibitory effect on 
Propionibacterium acnes and Staphylococcus epidermidis. Furthermore, 
Chomnawang  et al. (2007)  investigated that the activity of Thai medicinal plants on 
inflammation reduction caused by Propionibacterium acnes may be due to free 
radical scavenging and cytokine reducing properties. They found that Garcinia 
mangostana possessed the most significant antioxidant activity and reduced reactive 
oxygen species production. G. mangostana was highly effective in scavenging free 
radicals and was able to suppress the production of proinflammatory cytokines. This 
study has identified the promising source of anti-inflammatory agent which could be 
useful in treatment of acne vulgaris. Also, Chomnawang  et al. (2009)  showed that G. 
mangostana and its constituent, α-mangostin, had potent inhibitory effect against 
 
 
 
 
 
 
 
 
12 
 
methicillin-resistant S. aureus. In the same way, Sakagami et al. (2005) expressed that 
synergism between alpha-mangostin and gentamicin (GM) against vancomycin 
resistant Enterococci (VRE), alpha-mangostin and vancomycin hydrochloride (VCM) 
against methicillin resistant Staphylococcus aureus (MRSA) has occurred. These 
findings suggested that alpha-mangostin alone or in combination with GM or VCM 
against VRE or MRSA repectively might be useful in controlling VRE and MRSA 
infections. 
 2.1.3 Method for purification of active ingredient 
 Currently, the common methods that have been developed to purify the 
active ingredients from mangosteen generally involved using silica gel column 
chromatography. Chairungsrilerd et al. (1996a, b, c) extracted fresh fruit hull 
(pericarp) of G. mangostana with n-butanol and purified the extract on silica-gel 
column by eluting with CH2Cl2, CH2Cl2-MeOH (9:1), CH2Cl2-MeOH (4:1) and 
CH2Cl2-MeOH (1:1), respectively. Relatively less polar fractions gave known 
compounds as alpha mangostin, gamma mangostin and gartanin etc. They identified 
known compounds from their MS, IR, 
1
H and 
13
C NMR spectra. Successive 
purification of polar fraction by reverse phase HPLC using aq. MeOH as an elutent 
gave mangostanol. Besides, Govindachari et al. (1971) used silica gel column to 
purify active ingredients of different parts of mangosteen with various elutents. For 
example, partially ripe fruit was chromatographed using silica gel and eluted with 
benzene. The first 200 mL of elutate gave no material. The next 250 mL gave beta 
mangostin and the later 300 mL gave mangostin. In addition Sakagami et al. (2005.) 
extracted and isolated alpha-mangostin and beta-mangostin from stem bark of G. 
mangostana which was dried, powdered and extracted with hexane, methylene 
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chloride and methanol, respectively then used silica gel column chromatography with 
hexane, methylene chloride and methanol as solvent.  The hexane extract and 
methylene chloride extract gave two major compounds, alpha mangostin and beta-
mangostin as yellow needles. Apart from this, Chi et al. (2002) described isolation 
method in which the hull (pericarp) of mangosteen fruit was first dried at 60 ºC in an 
oven for 24 hour and 3 kg batches of the dried hulls were extracted with ethanol (25l) 
at 50 
º
C for about 16 hours. The extracts were pooled, concentrated by evaporation 
and then allowed to partition into aqueous and organic (EtOAc) phase. The EtOAc 
soluble fraction was then loaded into a silica gel column and eluted with gradient 
solvent system consisting of 10:l aliquots of each n-hexane-EtOAc (20:1, 10:1 and 
5:1), 7 L aliquots of each CH2Cl2-Me2CO (10:1, 5:1 and 0:1) and aliquots of each 
CH2Cl2-MeOH (10:1, 5:1 and 0:1) to yield 22 (~3 L) fractions. Fraction 13, the 
CH2Cl2-Me2CO (10:1) eluted fraction, was further chromatographed on a silica gel 
column equilibrated and eluted with n-hexane –EtOAc (5:1) to yield alpha mangostin 
or in Sephadex LH20 column equilibrated with MeOH-H2O (5:1) to yield gamma-
mangostin. 
 For the isolation method in this research, those of previous described 
methods were followed with little modifications.  
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2.2 Overview of microorganisms 
         2.2.1 Bacterial structure  
 
Figure 2.1 Show structure of bacterial cell. 
Source: http://www. microbeworld.org/img/aboutmicro/bacteria/bactdiag.gif. 
 
     The cytoplasmic membranes of gram-positive and gram-negative bacteria 
are indistinguishable. Each is composed of protein, lipids, phospholipids and a small 
amount of carbohydrate (Figure 2.1). It acts as an osmotic barrier, synthesizes the cell 
wall and provides a site to implant the chromosome. The other important functions are 
serving as the site of selective permeability, cytochrome activity, carrier-mediated 
transport and generation of proton motive force (PMF). 
  The periplasm is the space between the inner and outer membrane of a 
gram-negative bacterium, and the cell wall lies within it. The periplasm contains 
enzymes that hydrolyze large molecules, hydrolyze antibiotics, and binding protein 
that facilitate transport. 
 The cell wall is a web-like structure that is sometimes called the murien 
sacculus. It is composed of peptidoglycan. The cell wall provides the cell with its   
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sharp and osmotic stability. The cell wall constituents are peptidoglycan, teichoic 
acids and lipoteichoic acids. 
 Only gram-negative bacteria have an outer membrane. Porins and porin-
like protiens in the outer membrane allow the membrane to act as a molecular sieve, 
restricting the access of some molecules to the cell wall and periplasm. The most 
clinical significant component of the outer membrane is a phospholipid like molecule 
called lipopolysaccharide (LPS) (Walker, 1999).             
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Figure 2.2  Comparison of the thick cell wall of gram-positive bacteria with the 
comparatively thin cell wall of gram-negative bacteria. Note the 
complexity of the gram-negative cell envelope (outer membrane, its 
hydrophobic lipoprotein anchor; periplasmic space). 
Source: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.figgrp.294. 
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 2.2.2 Bacteria types 
     2.2.2.1 Staphylococcus saprophyticus (S. saprophyticus) 
 Family:  Staphylococcaceae 
 General characteristics 
 S. saprophyticus is a coagulase-negative species of 
Staphylococcus bacteria. It is often implicated in urinary tract infections. S. 
saprophyticus is resistant to antibiotic novobiocin, a characteristic that is used in 
laboratory identification to distinguish it from S. epidermidis, which is also coagulase- 
negative. The bacterium has a capacity for selective adherence to human urothelium. 
It causes direct hemagglutination. The adhesin for S. saprophyticus is a lactosamine 
structure. This staphylococcal species produces an extracellular enzyme complex that 
can inhibit growth of both gram-positive and gram-negative bacteria. It is rarely found 
in healthy humans but is commonly isolated from animals and their carcasses                 
(Shimeld and Rodgers, 1999). 
 Clinical significance 
 S. saprophyticus is implicated in 10-20% of urinary tract 
infections (UTI). In females between the ages of 17-27, it is the second most common 
cause of UTIs. It may also reside in the urinary tract and bladder of sexually active 
females.  Some of the symptoms of this bacteria are burning sensation when passing 
urine, the urge to urinate more often than usual, the “dripping effect” after urination, 
weak bladder, bloated feeling with sharp razor pains in the lower abdomen around the 
bladder and ovary areas and razor-like pains during sexual intercourse. (Shimeld and 
Rodgers, 1999). 
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 Antibiotic susceptibility characteristics 
 S. saprophyticus is usually susceptible to antibiotics commonly 
prescribed for patients with UTI, with the exception of nalidixic acid. Quinolones are 
commonly used in treatment of S. saprophyticus urinary tract infections (Shimeld and 
Rodgers, 1999) and resistance to penicillins such as oxacillin (Maharat 
Nakhonratchasima hospital, 2012). 
     2.2.2.2   Enterobacter cloacae (E. cloacae) 
 Family: Enterobacteriaceae 
 General characteristics 
 E. cloacae is a gram-negative, straight rod (0.6-1.0 μm wide 
x1.2-3.0 μm long). It is facultative anaerobe and chemoorganotrop. The optimal 
temperature for E. cloacae is 30-37 
º
C. It is widely distributed in nature and it can be 
found in soil, dairy products, water and sewage. It may also be present in the intestinal 
tract of humans and animals (Shimeld and Rodgers, 1999). 
 Clinical significance 
 E. cloacae generally does not cause disease in healthy individuals 
but significantly causes infections in immunocompromised or otherwise debilitated 
patients. This species is an opportunistic pathogen causing burn, wound and urinary 
tract infection and occasionally septicemia and meningitis (Shimeld and Rodgers, 
1999). 
 Antibiotic susceptibility characteristics 
 Most isolates of Enterobacter are resistant to ampicillin and first-
generation cephalosporins. Second- and third-generation cephalosporins may be 
effective (Shimeld and Rodgers, 1999). 
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     2.2.2.3  Escherichia coli (E. coli) 
 Family: Enterobacteriaceae 
 General characteristics: 
 E. coli is a gram-negative, straight rod (1.1-1.5 μm wide x2.0-6.0 
μm long) that occurs singly or in pairs. It is facultatively anaerobe and 
chemoorganotrophs. The optimal temperature for E. coli is 37 
º
C. It occurs as normal 
flora in the lower part of the intestine of warm-blooded animals (Shimeld and Rodgers, 
1999). 
 Clinical significance 
 E. coli normally colonizes an infant's gastrointestinal tract within 
40 hours of birth, arriving with food or water or with the individuals handling the 
child. In the bowel, it adheres to the mucus of the large intestine. It is the primary 
facultative organism of the human gastrointestinal tract.  As long as these bacteria do 
not acquire genetic elements encoding for virulence factors, they remain benign 
commensals. Virulent strains of  E. coli can cause gastroenteritis, urinary tract 
infections, and neonatal meningitis. In rarer cases, virulent strains are also responsible 
for haemolytic-uremic syndrome (HUS), peritonitis, mastitis, septicemia and gram-
negative pneumonia (Shimeld and Rodgers, 1999). 
 Antibiotic susceptibility characteristics 
 Antibiotics that generally have strong activity against E. coli  
include sulfonamides, ampicillin, cephalosporins, chloramphemicol, tetracyclines and 
aminoglycosides.  Sulfamethoxazole-trimethoprim and ciprofloxacin are usually very 
effective when treatment is started early (Shimeld and Rodgers, 1999) and resistance 
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to penicillins and cefalosporins such as ceftazidime (Maharat Nakhonratchasima 
hospital, 2012). 
 
2.3 Overview of antibiotics 
         2.3.1 β -Lactam  
 
                The β-lactam antibiotics are useful and frequently prescribed 
antimicrobial agents that share a common structure and mechanism of action-
inhibition of synthesis of the bacterial peptidoglycan cell wall (Laurence et al., 2006).  
The basic structure of β-lactam antibiotics consists of a five-membered 
thiazolidine ring fused to the β-lactam portion (Figure 12). Different types of 
antibiotics are determined side chain (R-group) (Tenover, 2006). 
 
 
 
 
 
 
 
Figure 2.3 Common structure of penicillin and site of cleavage by penicillinase 
(http://www.acessmedicine.com) 
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                   2.3.1.1 Beta-Lactam antibiotics 
                                 2.3.1.1.1 Penicillins 
                                                They are the most widely effective antibiotics and are 
among the least toxic drugs known; the major adverse reaction to penicillins is 
hypersensitivity. The members of this family differ from one another in the                          
R substituent attached to the 6-aminopenicillanic acid residue. The nature of this side 
chain affects their antimicrobial spectrum, stability to stomach acid, and susceptibility 
to bacterial degradative enzymes (β-lactamases). Figure 2.4 shows the classification 
of agents affecting cell wall synthesis (Mycek et al., 2000). 
                                 2.3.1.1.2 Cephalosporins 
                                                 Cephalosporins are similar to penicillins, but more 
stable to many bacterial β-lactamases and therefore have a broader spectrum of 
activity. However, strains of E. coli and Klebsiella species expressing extended-
spectrum β-lactamases that can hydrolyze most cephalosporins are becoming               
a problem. Cephalosporins are not active against enterococci and L. monocytogenes 
(Katzung, 2006). 
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Figure 2.4 Summary of antimicrobial agents that inhibit cell wall synthesis. 
Source: Mycek et al. (2000). 
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  2.3.1.2 The use of β-lactam antibiotics 
                                2.3.1.2.1 Oxacillin 
 
                                   
 
 
 
 
 
 
Molecular formular: C19H19N3O5S
 
 
Molecular mass: 401.436 g/mol 
Solubility: Soluble in water and methanol  
Appearance: Fine white crystalline powder 
(http://en.wikipedia.org/wiki/Oxacillin) 
 
Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of 
bacterial infections caused by susceptible, usually gram-positive, organisms. The 
name "penicillin" can either refer to several variants of penicillin available, or to the 
group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against 
gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal 
activity of oxacillin results from the inhibition of cell wall synthesis and is mediated 
through oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable 
against hydrolysis by a variety of beta-lactamases, including penicillinases, and 
cephalosporinases and extended spectrum beta-lactamases.   Machanism of action by 
binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell 
wall, oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell 
lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is 
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possible that oxacillin interferes with an autolysin inhibition   
(http://www.onlinepharmacycatalog.com/category/common-drugs-and-medications 
/antibiotics/oxacillin/). 
 
                         2.3.1.2.2 Ceftazidime 
 
                                            
 
 
 
 
 
 
Molecular formular: C22H22N6O7S2
 
 
Molecular mass: 546.58 g/mol 
Solubility: Soluble in water  
Appearance: white or almost white powder 
(http://en.wikipedia.org/wiki/Ceftazidime) 
 
Ceftazidime is a semisynthetic, broad-spectrum, β-lactam antibiotic for 
parenteral administration. Ceftazidime is bactericidal in action exerting its effect by 
inhibition of enzymes responsible for cell-wall synthesis. A wide range of Gram-
negative organisms is susceptible to ceftazidime in vitro, including strains resistant to 
gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be 
active against Gram-positive organisms. It is highly stable to most clinically important 
β-lactamases, plasmid or chromosomal, which are produced by both Gram-negative 
and Gram-positive organisms and, consequently, is active against many strains 
resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the 
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gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against 
Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins. 
The bactericidal activity of ceftazidime results from the inhibition of cell wall 
synthesis via affinity for penicillin-binding proteins (PBPs) (Goodman and Gillman, 
2005). 
 2.3.1.3 Mechanisms of bacterial resistance to penicillins and                                                                                                   
cephalosporins 
                             Although all bacteria with cell walls contain penicillin-binding 
protein (PBPs), β-lactam antibiotics cannot kill or even inhibit all bacteria because by 
various mechanisms bacteria can be resistant to these agents. The microorganism may 
be intrinsically resistant because of structural differences in the PBPs that are the 
targets of these drugs. Furthermore, a sensitive strain may acquire resistance of this 
type by the development of high-molecular-weight PBPs that have decreased affinity 
for the antibiotic. Because the β-lactam antibiotics inhibit many different PBPs in a 
single bacterium, the affinity for β-lactam antibiotics of several PBPs must decrease 
for the organism to be resistant. Altered PBPs with decreased affinity for β-lactam 
antibiotics are acquired by homologous recombination between PBP genes of 
different bacterial species. Four of the five high-molecular-weight PBPs of the most 
highly penicillin-resistant Streptococcus pneumoniae isolates have decreased affinity 
for β-lactam antibiotics as a result of interspecies homologous recombination events 
(Laurence et al., 2006).  
            2.3.1.4 Mechanisms of antimicrobial resistance 
                              Bacteria can have an intrinsic immunity to a particular antibiotic 
because of biochemical structure and/or function. They may simply not respond to the 
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antibiotic mechanism of action. Bacteria can also acquire resistance to a drug in one 
of two ways. Primary resistance occurs through spontaneous mutation, which is a rare 
event. Resistance is then transferred to progeny. Bacteria replicate asexually, so all off 
spring of a resistant bacteria will inherit the resistant gene. Secondary resistance 
requires a transfer of genetic material between same or different species of bacteria 
through transduction, transformation, although reproduction in or conjugation  (Table 
2.1). Bacteria are asexual; they can share genetic material by forming  a conjugation 
bridge with bacteria from the same or different species (Figure 2.5). Genetic material 
is carried on plasmids or transporans. Genetic transfer may confer multidrug-
resistance and cross-resistance, where by resistance to one drug in a class translates 
into resistance to other antimicrobial drugs in that class. The ease with which bacteria 
share genetic material accounts for most antimicrobial resistance. 
 
Table 2.1 How bacteria transfer genetic material. 
How Bacteria Transfer Genetic Material 
Transduction Viruses carry genetic material from one bacterium to  
 
another 
 
Transformation Bacteria engulf genetic material from dead bacteria in  
 
the environment 
 
Conjugation  
 
(most common) 
Two bacteria join cells and transfer genetic material via  
 
Plasmids 
 
Source: Roe (2008). 
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Figure 2.5  Bacterial conjugation. 
Source: Roe (2008). 
 
 Once an antimicrobial enters the bacteria, it must bind to                       
a specific biochemical target site in order to interfere with cell metabolism. 
Genetically altered bacteria can combat antibiotics in several ways (Figure 2.6). They 
may synthesize enzymes that destroy the drug or chemically modify it so that it 
becomes inactive. For example, some β-lactamase, which destroys  β-lactam ring 
common to the structure of β-lactam antibiotics. Resistance to the β-lactam is 
widespread in both gram-positive (Staphylococci) and gram-negative (Neisseria 
gonorrhoea, Escherichia coli, and Haemophilus influenza) species. Some β-lactam 
antimicrobials, the antistaphylococcal penicillins (methicillin, nafcillin, oxacillin, and 
dicloxacillin), were developed specifically to avoid the effects of the β-lactamase 
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producing bacteria. Dicloxacillin is the only member of this group of antibiotics 
available in oral form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Mechanisms of antibiotic resistance.  
Source: Roe (2008). 
 
      2.3.1.4.1 Enzyme-based resistance  
    Bacterial resistance to antibiotics is most often 
mediated by the bacterial synthesis of  β-lactamase enzymes. These are the main 
cause of bacterial resistance to penicillins and cephalosporins. Definitive 
identification of these enzymes is only possible by gene or protein sequencing 
(Livermore and Brown, 2001). 
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    2.3.1.4.2 Ribosomal modifications  
                    The ribosome can be methylated so that an antibiotic 
cannot bind to it (Tenover, 2006). 
     2.3.1.4.3 Protein modifications  
    For antibiotics that target DNA gyrase, the enzyme that 
unwinds DNA for replication, random mutations in the bacterial DNA may alter the 
gyrase and make it unrecognizable to antibiotics while still leaving it functional 
(Tenover, 2006). 
    The penicillin-binding protein (PBPs) occur in the 
bacterial cell wall and have an enzymatic role in the synthesis of peptidoglycan. PBPs 
normally possess a high affinity for β-lactam antibiotics, in MRSA this affinity is 
reduced resulting in antibiotic resistance. MRSA carry the mecA gene which encodes 
affinity penicillin binding protein, known as PBP2a (Cook, 1998). 
     2.3.1.4.4 Metabolic resistance  
     In the case of sulfonamides, which operate by 
mimicking PABA and competing for an enzyme that synthesizes folic acid, an 
increase in the amount of PABA can outcompete the sulfonamide and render it 
ineffective; or an alteration in the code for the enzyme itself can prevent its 
sulfonamide binding (Tenover, 2006). 
     2.3.1.4.5 Effluxing the toxin  
    Antibiotic efflux pumps are nowadays believed to 
significantly contribute to acquire bacterial resistance because of the very broad 
variety of substrates they recognize, their expression in important pathogens, and their 
cooperation with other mechanisms of resistance.  Their existence also explains many 
situations of apparent intrinsic resistance of specific organisms (Seral et al., 2003).  
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For example, a strain of Enterococcal bacteria can pump out tetracycline. This type of 
pumping is called an “efflux phenomenon” (Tenover, 2006). 
     2.3.1.4.6 Acquired resistance 
    Bacteria also develop resistance through the 
acquisition of new genetic material from other resistant organisms. This is termed 
horizontal evolution, and may occur between strains of the same species or between 
different bacterial species or genera. Mechanisms of genetic exchange include 
conjugation, transduction, and transformation. Through genetic exchange 
mechanisms, many bacteria have become resistant to multiple classes of antibacterial 
agent (Roe, 2008; Tenover, 2006). 
  2.3.1.4.7 Transduction 
    A virus (bacteriophage) serves as the agent of transfer 
DNA segment between bacterial strains (McManus, 1997). When a phage is being 
replicated inside a host cell, the new viruses self-assemble from proteins and viral 
nucleic acid (genetic material) that the host cell has produced. Sometimes some of the 
DNA of the host, which had been chopped up during the lytic replication process, gets 
inside a new virus during viral self-assembly. When that phage then infects another 
cell, the new host may incorporate the donated DNA into its chromosome by 
recombination (Bauman, 2005). 
   2.3.1.4.8 Transformation 
    This is the process in which a recipient cell takes up 
DNA from the environment (such as DNA released from a dead organism) (Port, 
2008). After the new DNA is introduced via transformation it is incorporated DNA 
segments into the cell and results in the emergence of a new, resistant genotype 
(McManus, 1997). 
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    2.3.1.4.9 Conjugation 
    Transmission of resistance genes via plasmid 
exchange. Bacteria have circles of DNA called plasmids that they can pass to other 
bacteria during conjugation. Plasmids is the key players in conjugation, are even 
referred to as resistance transfer factors. During conjugation, a gram-negative 
bacterium transfers plasmid-containing resistance genes to an adjacent bacterium, 
often via an elongated protein aqueous structure termed a pilus, which joins the two 
organisms. Conjugation among gram-positive bacteria is usually initiated by 
production of sex pheromones by the mating pair, which facilitate the clumping of 
donor and recipient organisms, allowing the exchange of DNA. This type of 
acquisition allows resistance to spread among a population of bacterial cells much 
faster than simple mutation and vertical evolution would permit (McManus, 1997). 
 
Figure 2.7  Bacteria transfer genetic material. 
                 (http://www.wiley.com/college/) 
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2.4 Laboratory methods used for antimicrobial susceptibility testing 
         The inhibitory activity of an antimicrobial agent is determined by dilution 
testing, which produces a quantitative result. The decision concerning which method 
to used is based on several factors including cost, ease of use, flexibility, and degree 
of automation (Swan and Manivannan, 2000). 
         2.4.1 Susceptibility test method 
                    Dilution Testing: 
                    Dilution susceptibility tests determine the minimal concentration of an 
antimicrobial agent needed to inhibit growth of the microorganism being tested. For 
most dilution tests, antimicrobial agents are tested at log 2 (two-fold) serial dilutions. 
The lowest concentration at which there is no visible growth is called the minimal 
inhibitory concentration (MIC) (Swan and Manivannan, 2000). 
 2.4.2 Checkerboard results 
       When two antimicrobial agents act simultaneously on a homogeneous 
microbial population, the effect may be one of following. 
                   (1) No interaction; The combined action is equivalent to the sum of the 
actions of each drug when used alone (FIC index > 0.5-4.0). 
                   (2) Synergism; The combined action is significantly greater than the sum 
of  both effects (FIC index ≤ 0.5). 
                   3. Antagonism; The combined action is less than that of more effective 
agent  when used alone (FIC index >4.0) (American Society for Microbiology, 2004; 
John, 2004; Odds, 2003). 
 The most popular method used to detect antimicrobial interaction is 
checkerboard or chessboard titration, in which two drugs are cross-titrated against 
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each other (Sawan and Manivanna, 2000). After incubation, the isobologram is 
constructed by plotting the inhibition of growth observed at each drug concentration 
on an arithmetic scale. The line of additive joins the MICs of the individual drugs 
acting alone, a deviation of this line towards the axes of the graph suggests synergy; a 
deviation away from the axes is often taken to indicate antagonism, although in 
difference may also produce this result (Sawan and Manivannan, 2000).  
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1 Materials 
 3.1.1 Plant species 
          The mangosteen fruits (Garcinia mangostana L.) were purchased from                   
a local market in Nakhon Ratchasima, Thailand. The specimen of this plant was 
authenticated with a voucher specimen at the Forest Herbarium, Bangkok, Thailand. 
The pericarps of mature mangosteen fruits were extracted to get α-mangostin or other 
bioactive compounds. The extraction and identification methods are mentioned in this 
chapter.  
 3.1.2 Test organisms 
                    3.1.2.1 Bacterial strains 
                      Clinical isolates of Staphylococcus saprophyticus DMST 27055                                  
(S. saprophyticus), clinical isolates of Enterobacter cloacae DMST 21394                
(E. cloacae) and  clinical isolates of Escherichia coli DMST 19629 (E. coli), Clinical 
isolates of Staphylococcus aureus ATCC 29213 (S. aureus) and clinical isolates of 
Escherichia coli ATCC 25922 (E. coli) were obtained from the Department of 
Medical Science, National Institute of Health, Ministry of Public Health, Thailand and 
the American Type Culture Collection (ATCC), USA. 
 
 
 
 
 
 
 
 
 
 
35 
 
 3.1.2.2 Preparation and maintenance of stock cultures 
                                  The clinical isolates of bacteria were inoculated on nutrient agar 
slopes and incubated overnight at 37 
°
C. These cultures were stored in a refrigerator  at 
4 
°
C. Fresh slope cultures were prepared every 3-4 weeks (Eumkeb, 1999). 
 3.1.3 β-lactam antibiotics 
  Oxacillin and ceftazidime were obtained from Sigma, Bristol-Myers. 
 3.1.4 Culture media 
                    Nutrient agar, Mueller-Hinton broth and agar were obtained from Oxiod. 
Apigenin, α-mangostin were obtained from Indofine chemical company (The 
Flavonoid Company, USA). 
                   Approximate formula per liter of each medium was as following: 
         3.1.4.1 Nutrient agar 
 HiMedia

 nutrient agar was used for preparation of stock cultures 
on agar slopes and the basic agar culture of bacterial cells for colony counting. 
The formula was: 
g/L 
Peptic digest of animal tissue     5.0 
Sodium chloride       5.0 
Beef extract        1.5 
Yeast extract        1.5 
Agar         1.5 
pH (at 25 
°
C) 7.4 ± 0.2 
 
 
 
 
 
 
 
 
 
 
36 
 
            3.1.4.2 Mueller-Hinton broth (MHB) 
 Difco

 Mueller Hinton broth was the medium used for 
determining the antimicrobial susceptibility testing. 
 The formula was: 
         g/L 
Beef infusion solids       4.0 
Casein hydrolysate                17.5 
Soluble starch       1.5 
pH 7.4 ± 0.2 at 37 
º
C 
Mueller-Hinton had been cation-adjusted that had the corrected  
concentrations of the divalent cations of Ca
2+
 20 mg/L and Mg
2+
 10 mg/L. 
All culture media were dissolved by water. 
3.1.4.3 Mueller-Hinton agar (MHA) 
Difco

 Mueller Hinton agar was the medium used for 
determining the antimicrobial susceptibility testing. 
The formula was: 
         g/L 
Agar                  17.0 
Beef heart infusion          2 
Casien acid hydrolysate                   17.5 
Soluble starch       1.5 
pH 7.3 ± 0.2 at 25 
º
C 
 3.1.5   Chemicals    
           All chemicals used were laboratory grade otherwise specified. 
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Ethanol absolute      Lab grade 
Hexane        Lab grade 
Dichloromethane       Lab grade 
Acetone        Lab grade 
Ethyl acetate        Lab grade 
Silica gel         
      Merck silica gel 60 Art. 7734 (70-230 mesh ASTM) was used 
as adsorbent for normal column chromatography.  
         Merck silica gel 60 G Art. 7731 and 60 GF254 Art. 7730 were 
applied as adsorbent for preparative TLC. 
                   Merck TLC aluminum sheet, silica gel 60 F254 precoated 20 cm 
x 20 cm in size with layer thickness of 0.2 mm was used to identify the identical 
fractions. 
Dimethylsulfoxide (DMSO)      AR grade 
Disodium tetraborate       Lab grade 
Sodium chloride       AR grade 
Sodium phosphate       Lab grade 
Sodium hydroxide       Lab grade 
95% Ethanol        Lab grade 
Ammonium acetate       AR grade 
Acetronitrile        Lab grade 
Albumin        AR grade 
Lecithin        Lab grade 
Tween 80        Lab grade 
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Paraformaldehyde       Lab grade 
Glutaraldehyde       Lab grade 
Osmiun tetroxide       Lab grade 
Methanol        Lab grade 
Araldite        Lab grade 
Agarose        Lab grade 
Uranyl acetate       Lab grade 
Lead acetate        Lab grade 
HEPES buffer       Lab grade 
Phosphate        Lab grade 
PMSF         Lab grade 
Triton X-100        Lab grade 
Ceftazidime        AR grade 
Oxacillin        AR grade 
α-mangostin        AR grade 
3.1.6 Equipments 
          3.1.6.1  Apparatus 
   Rotary evaporator              Büchi 
     Heating bath: Büchi heating bath B-490 
Rotavapor: Büchi rotavapor R-200 
Controller: Büchi vacuum controller V-800  
           UV-Cabinet II                       Camag   
             NMR Spectrometer INOVA 300             Varian 
   Soxhlet apparatus               Büchi 
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   Mixer (Model 5000)                      Büchi 
Hot air oven (Memmert-600)                                           Shellab 
Column chromatography                                                   Merck 
Filter paper                                                                    Whatman 
Tank of TLC analysis                                                         Merck 
Spectronic 21                 Milton Roy 
Labofuge             400R Heraeus 
Autoclave            Yamato 
Laminar air flow         Woerden 
Hot air oven                  Shellab 
Shaking incubator                Heto 
Hot plate            VELP scientifica 
Refrigerated incubator      VELP scientifica 
Ultramicrotome                JEM 
Micropipettors (2-20 μL)             Witeg 
Micropipettors (100-1000 μL)            Witeg 
Centrifuge tubes               Pyrex 
Spectraphysics            Agilent 
  3.1.6.2 Glasswares 
Beakers (50, 100, 250, 500, 1000 mL)  
Pipettes (1, 5, 10 μL)  
Measuring cylinder (10, 20 μL)  
Petri dishes  
Test tubes  
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3.2 Methods 
 3.2.1 Extraction of compounds from the mangosteen fruit 
       Pericarps of mangosteen fruit were dried under a hot air oven and were 
powdered by mixer then were extracted using Soxhlet extractor. Hexane, acetone, 
dichloromethane, and Ethanol were used as solvent systems (1 kg dried mangosteen 
pericarp powder/ 3000 mL solvent/ extraction). The temperature of the extraction 
process was set at 75 
°
C for 8 hours. Each extract was concentrated in a rotary 
evaporator  to give a brown sticky semi-solid for ethanol (262 g) and acetone (130 g) 
and yellowish powder for n-hexane (84 g) and dichloromethane (106 g). The crude 
extracts were isolated using column chromatography and thin layer chromatography.  
 3.2.2 Isolation of active compounds 
                   The method for isolating the compounds from pericarp of mangosteen fruit 
procedure was based on those by Chairungsrilerd et al. (1996a, b, c), Chi et al. (2002) 
and Sakagami et al. (2005) with little modifications. The dichloromethane crude 
extract was subjected to silica gel column chromatography to yield eleven fractions,  
1-11 on the successive elution with ethyl acetate: hexane system, of 10:90, 20:80, 
30:70,  35:65, 40:60, 45:55, 50:50, 60:40, 70:30, 80:20 and 100:0, respectively. Every 
fraction of 1000 mL was collected and concentrated to a small volume and then was 
separated by monitoring with TLC (2 x 5 cm
2
 in size with ethyl acetate: hexane, 1:1 as 
developing solvent). Fraction 3 was confirmed by HPLC to contain α-mangostin and 
further purified by preparative thin layer chromatography (hexane:acetone 2:1) to give 
the main component, a yellowish crystalline compound. The purification of this 
compound was confirmed by Thin layer chromatography with dichloromethane: 
hexane system (50:50) under UV condition and its structure continued to be elucidated 
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by NMR  at the Center for Scientific and Technological Equipment (CSTE), Suranaree 
University of Technology and compared with the structure spectrum data of previous 
papers. 
 3.2.3 Preparation of test solution and inoculums 
      Antibiotic test solutions were prepared by dissolving Oxacillin and 
Ceftazidime (1 mg/mL) in sterile water.  
     A solution (10% dimethylsulfoxide in water) of crude extract and/or                    
α-mangostin or other bioactive compounds (CH2Cl2 crude extract, fr3 extract and                 
α-mangostin) from the pericarp of GML extract alone and in combination with 
selected drugs were  prepared by the doubling dilution method with sterilized water 
and adjustment to give the required test concentrations.  
      Test organisms were incubated in 100 mL nutrient broth for 18 h at 37 
º
C.  
The cell cultures were centrifuged at 4,000 r.p.m for 10 min. The cell pelletes were 
washed with saline, recentrifuged and resuspended in saline. The cell concentrations 
were adjusted with saline to give 5 x 10
8
 CFU/mL using a predetermined calibration 
curve of absorbance at 500 nm against viable count (Liu et al., 2000). The MICs of 
crude extract, fr3 extract, α-mangostin and the selected antibiotics alone and there 
extraction in combination with each antibiotic were examined. 
 3.2.4  Bacterial suspension standard curve 
     To select bacterial suspensions with a known viable count the following 
steps were followed: 
 A separate loopful of each bacterium was used to inoculate in 100 mL of 
Mueller Hinton broth. The cultures were incubated at 37
 °
C for 18 h. The bacterial 
cells were pelletted by centrifugation at 4,000 r.p.m. for 10 min. The cells were 
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washed twice by resuspending and centrifuging at 4,000 r.p.m/min for 10 min in       
10 mL of 0.9% NaCl. The cells were resuspended in 50 mL of sterile 0.9% NaCl.   
The cell suspensions were diluted so that 5-6 spectrophotometer readings could be 
obtained over the absorbance range of approximately 0.05-0.25 at a wavelength of  
500 nm. Viable counts for each absorbance reading were determined in triplicates 
using  overdried agar plate counting method. (Eumkeb, 1999; Richards et al., 1993). 
 3.2.5 MICs determination 
 Conventional broth dilution tests were used when only a few strains                     
of bacteria needed to be tested or when an accurate MIC estimation was required.                
A series of two-fold dilutions of the antibiotic under study was prepared in a volume 
of a suitable medium and a standard inoculum of the test strain (commonly 100,000 
bacteria) was introduced into each tube. The test was incubated at 37 
º
C overnight              
and the end-point was read that concentration of antibiotic in which no turbidity can 
be seen. Uninoculated tubes containing broth plus antibiotic and broth alone act as 
sterility controls. An antibiotic-free tube inoculated with the test organism serves to 
indicated that the organism is viable in case the end-point was missed (Greenwood, 
2000). 
 MICs were determined using an agar dilution method. The sterile wire 
loop test organism from a slope culture was inoculated into Mueller Hinton broth and 
was incubated for 18 h at 37 
°
C. Then, preparation of a bacterial suspension, the 
density of the bacterial suspension in normal saline was adjusted to approximately                        
1 x 10
8
 CFU/mL by using the absorption of bacterial suspension viable count standard 
curve. The inoculum of 0.1 mL of standard of suspension (18 h culture) of each strain 
of the test bacteria was added to triplicate tubes containing 0.90 mL (MHB for the 
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tested strains), plus serial dilutions of the antibacterials, to give approximately                       
1 x 10
7
 CFU/mL. Tubes of broth without antibacterials were used as the control for 
each of the test bacteria. Applied an aliquot of each inoculums to the agar surface 
which deliver 2 μL by using replicators with 3 mm pins. The final inoculum on the 
agar was approximately 10
4
 CFU/spot. Incubation was at 37 
°
C for 16-24 h. The MICs 
were defined as the lowest concentration of antibiotic at which there is no visible 
growth in the triplicate spots (CLSI, 2013; Eumkeb, 1999; Wikler et al., 2006). 
 3.2.6 Checkerboard determination 
  Antimicrobial combinations were selected for various reasons, including 
minimizing drug toxicity by using the lowest possible doses of two or more agents that 
have additive efficacies but independent toxicities, or reducing the potential for 
development of resistance to one agent (Swan and Manivannan, 2000). Checkerboard 
titrations are relatively simple to perform and allow the assessment synergy at 24 h 
only. Dilution of antimicrobial agents may reduce to concentrations tested to a level at 
which synergy cannot be detected (Eumkeb, 1999; Lorian, 1999). 
 Checkerboard determinations in antimicrobial combinations were 
performed following the method of Sabath (1967) with slight modification (Eumkeb, 
1999). Antibacterial agent “A” and antibacterial agent “B” were diluted to 1/2 of their 
MICs along the ordinate and abcissa respectively. The checkerboard assays were done 
using agar dilution method as follows. 
 An 18 h culture of each of the test bacteria was prepared. The test bacterial 
suspensions were adjusted to 1 x 10
8 
CFU/mL using the absorption of bacterial 
suspension from the previously determine standard curve. The inoculum of 0.1 mL of 
standard of suspension (18 h culture) of each strain of the test bacteria was added to 
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triplicate tubes containing 0.90 mL (MHB for the tested strains), plus serial dilutions 
of the antibacterials, to give approximately 1 x 10
7
 CFU/mL. Tubes of broth without 
antibacterials were used as the controls for each of the test bacteria. Applied an aliquot 
of each inoculums to the agar surface which deliver 2 μL by using replicators with      
3 mm pins. The final inoculum on the agar was approximately 10
4
 CFU/spot.          
The culture was incubated for 18-24 h at 37 
º
C. The test was carried out in triplicate. 
MICs were determined for each antibacterial combination and the isobolograms were 
plotted. The calculation of the FIC (Minimum Inhibitory Concentration) index for 
each antibacterial combination was undertaken as follows: 
 
 
 
FIC (A+B)  ≤ 0.5   Synergy 
FIC (A+B)  > 0.5-4.0  No interaction 
FIC (A+B)  > 4.0   Antagonism 
       (American Society for Microbiology, 2004; Johnson, 2004; Odds, 2003) 
 3.2.7 Killing curve determinations 
     Viable counts for the determination of the killing curve were performed                    
as previously described (Richards and Xing, 1996) with slight modification (Eumkeb, 
1999) using a culture medium volume of 100 mL. Inocula of 5 x 10
6
 CFU/mL of drug 
resistant bacteria were exposed to the antibacterials either singly or in combination 
with antibiotic drugs at concentrations ¼  of their MICs of CH2Cl2 crude extract, fr3 
extract and α-mangostin (bioactive compounds from the pericarp of GML extract) an 
incubation temperature of 37 
°
C. After contact time of 0, 0.5, 1, 2, 4, 6, and 24 h. 
FIC  =         Conc. of A in MIC of A+B   +   Conc. of B in MIC of A+B 
                               MIC of A alone                           MIC of B alone 
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Subsequent dilution plating on overdried Mueller Hinton agar plates in quadruplicate 
and incubation at 37 
°
C for 18 h allowed counting of growing colonies. The lowest 
detectable limit for counting is 10
3
 CFU/mL. Positive controls were used containing 
similar cell and solvent concentrations (Wikler et al., 2006). 
 3.2.8 Transmission electronmicroscopy (TEM) method 
    Preparation of cultures 
    To examine the effect of drugs, CH2Cl2 crude extract, fr3 extract and                            
α-mangostin on the cell structure of oxacillin-resistant S. saprophyticus, the following 
mehtods were performed. 
 S. saprophyticus was incubated in 10 mL Mueller Hinton broth for 18 h at 
37 
°
C. A 2.0 mL volume of 18 h culture was inoculated into a 250 mL conical flask 
containing 98 mL Mueller Hinton broth which was placed in a water bath shaking at 
100 oscillations/min for 4 h at 37 
°
C. The cells were then washed two times by 
suspending and centrifuging at 4,000 r.p.m. for 10 min in 0.9% NaCl. Volume of              
10 mL of 5 x 10
7
 of CFU/mL in 0.9% NaCl was inoculated into 250 mL conical flasks 
each containing 90 mL Mueller Hinton broth plus antibiotic drugs at concentrations ¼  
of their MICs of CH2Cl2 crude extract, fr3 extract and  α-mangostin plus selected 
antibacterial to give approximately 5 x 10
6
 CFU/mL final concentration. A flask 
containing 90 mL MHB for S. saprophyticus without any antibiotics was used as the 
control. The cultures together with the appropriate bioactive compounds from the 
pericarp of GML extract plus antibacterial and control cultures were incubated for 4 h 
shaking at 100 oscillations/min in a water bath at 37 
°
C (Richards et al., 1993; Xing, 
1994). 
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 The S. saprophyticus cultures were centrifuged at 6,000 g for 15 min at              
4 
°
C and the supernate was removed. The pellets were fixed in glutaraldehyde                 
8% v/v in 0.1 M phosphate buffer (pH 7.2), for 1 h at 4 °C and then were fixed in 
4%v/v glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for 4 h at 4 
°
C. After 
washing in the buffer the bacteria were suspended in osmium tetroxide (OsO4, 
Emscope, Watford), 1% w/v, for 1 h at room temperature. They were then washed 
three times by centrifugation and resuspended in distilled water. The final pellet were 
resuspended in a small volume of warm agarose 2% w/v, poured onto a glass slide and 
were allowed to cool. When set, small pieces of gel containing suspended bacteria 
were cut out and dehydrated through a grade series of ethanol solutions. After 
embedding in resin, thin sections were cut with a diamond knife on an RMC 
ultramicrotome model MTX, stained with uranyl acetate and lead citrate, and 
examined in a JEOL, JEM 2010 electron microscope at 80-100 kV (Eumkeb, 1999; 
Richards et al., 1993). 
 3.2.9 Outer and Cytoplasmic membrane permeability 
      3.2.9.1 Outer membrane (OM) permeability 
 To examine the effect of antibacterial characteristic of bioactive 
compounds from the pericarp of GML extract (CH2Cl2 crude extract, fr3 extract and  
α-mangostin) alone or in combination with antibiotics on the function of the OM as a 
permeability barrier, the following method was performed. 
 The cell cultures were incubated in 100 mL MHB for 18 h at      
37 
°
C. Inocula of 10 mL of quantities of 18 h culture were added to 250 mL conical 
flasks containing 90 mL MHB in shaking water bath at 37 
°
C and shaking at 100 
oscillations/min for 4 h. Inocula of 5 x 10
6
 of CFU/mL for 10 mL of the 4 h log phase 
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culture were added to 250 mL conical flasks each containing 90 mL MHB plus 
CH2Cl2 crude extract, fr3 extract and α-mangostin alone or in combination with 
antibiotic drugs at concentrations ¼ of their MICs against bacteria to give final 
concentration approximately  5 x 10
5
 CFU/mL. The control flasks containing 90 mL 
MHB without antibiotics were used as control. The flasks were incubated at 37 
°
C for 
4 h in a shaking water bath (Eumkeb, 1999; Richards et al., 1993). The resulting 
cultures were harvested by centrifuging at 4,000 rpm for 10 min followed by washing 
the cells two times in 10 mL 0.9% NaCl. The cells were resuspended in sodium 
phosphate buffer and adjusted to an absorbance reading of 0.1-0.2 at 500 nm. The cell 
suspensions were treated with Triton X-100 (TTX-100) at a final concentration of   
300 µg/mL in each tube. Cell suspensions without TTX-100 were used as control 
(Eumkeb, 1999). 
                 3.2.9.2 Cytoplasmic membrane (CM) permeability 
        Cytoplasmic membrane permeability was determined by the 
ability of the peptides to unmask cytoplasmic β-galactosidase activity in bacteria by 
using ortho-nitrophenylgalactoside (ONPG) as the substrate. The method of sample 
preparation was prepared the same as for the OM permeability determinations. Then, 
0.5 mL of culture were transferred from each flask at 0, 1, 2, 3, 4, and 5 h. These 
samples were diluted to 1.0 mL with buffer. Beta-galactosidase activity was measured 
using ONPG (Marri et al., 1996; Miller, 1972). The method to assay of beta-
galactosidase was as follows:  
        The cell density of a diluted culture in assay buffer was 
determined by measuring the absorbance at 600 nm. Volume of 0.2 mL of ONPG               
(4 mg/mL) was added to each tube and shaken for a few seconds. The tubes were 
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placed in a water bath at 37 
°
C. The time of the reaction was determined with a stop 
watch and the reaction stopped by adding 0.5 mL of a 1 M Na2CO3 solution after 
sufficient yellow colour had developed. The absorption was recorded at 420 nm for 
each tube. Toluene 50 µl/mL was used as a positive control (Eumkeb, 1999). 
      3.2.10 Electrophoresis 
          3.2.10.1 Extraction of bacterial membrane peptidoglycan-associated 
protein  
        To examine the effect of antibacterial characteristic from 
bioactive compounds from the pericarp of GML extract (CH2Cl2 crude extract, fr3 
extract and α-mangostin)  alone and in combination with antibiotic drugs on the 
bacterial membrane and peptidoglycan associated protein (BMPG). The following 
method was practiced.  
 S. saprophyticus was incubated in 100 mL quantities of 
Mueller Hinton broth for 18 h at 37 
°
C. An 8.0 mL volume of 18 h culture was 
inoculated into a 250 mL conical flask containing 192 mL Mueller Hinton broth which 
was place in a water bath shaking at 100 oscillations/min for 4 h at 37 
°
C. Volumes of 
100 mL of  1 x 10
6
 CFU/mL for the 4 h log phase culture were inoculated into 250 mL 
conical flasks each containing 100 mL Mueller Hinton broth plus concentrations ¼  of 
their MICs of CH2Cl2 crude extract, fr3 extract and α-mangostin plus selected 
antibacterial. A flask containing 100 mL Mueller Hinton broth without any 
antibacterials was used as the control. The log phase cultures together with the 
concentrations ¼ of their MICs of bioactive compounds from the pericarp of GML 
extract plus antibacterial and log phase control culture were incubated for 4 h shaking 
at 100 oscillations/min in a water bath at 37 
°
C. Bioactive compounds from the 
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pericarp of GML extract and drugs were used singly or in combination at ¼ MIC for 
clinical isolates of S. saprophyticus (Eumkeb, 1999; Richards et al., 1993; Xing, 
1994). 
 A 200 mL of bacterial culture was harvested by centrifugation 
(15 min, 6,000 g, 4 
°
C) and washed twice with N-2-hydroxyethyl piperazine-N,-
ethanesulphonic acid (HEPES) buffer (10 mM, pH 6.8). The bacteria were 
resuspended in 10 mL diluted water and disintegrated by sonication (3 x 60 s with                
a 30 s cooling period between each burst) at 4 
°
C. Unbroken cells were removed by 
centrifugation at 5,000 g, 4 
°
C for 5 min and the pellet was discarded.  
 The bacterial membrane and peptidoglycan complex was 
recovered by centrifugation at 40,000 g for 60 min, washed twice in distilled water 
containing 2 mg/mL phenyl methyl sulphonyl fluoride (PMSF). Then, the same 
precise weight (25 mg) of BMPG extract of each sample from S. saprophyticus was 
resuspended in 0.5 mL of (distilled water + 2 mL/mL PMSF). Therefore, the same 
quatity of BMPG extract of each sample (50 mg/mL) from S. saprophyticus could be 
investigated. These extract proteins were then stored frozen at -70 
°
C (Eumkeb, 1999; 
Richards and Xing, 1996; Williams and Gledhill, 1991). 
 Bovine serum albumin (from Sigma) was used as the protein 
standard. The extract was stored at -70 
°
C and re-diluted in sample buffer before               
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) separation. The extract was 
shown to be stable for over 2 months under these conditions (Eumkeb, 1999). 
 3.2.10.2 SDS-PAGE 
           SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used a gel system having a 4% stacking gel and a 15% separating gel. A volume of the 
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BMPG extract was  mixed with a volume of sample buffer containing  0.125 M Tris-
HCl buffer, pH 6.8, containing 0.04 M Na2EDTA (Sigma), 4% w/v SDS, 10% w/v    
β-mercaptoethanol, 20% v/v glycerol and 0.1% w/v bromophenol blue (Sigma) and 
boiled for 5 min. The electrophoresis was performed at 8 mA per gel for stacking gel 
and 15 mA per gel for separating gel to maximize the resolution at the important 
subtyping areas of the gel. After electrophoresis the separating gel was stained with a 
Coomassie Brilliant Blue stain for 2 h at room temperature with gentle mixing. The 
gel was initially destained with 45% v/v ethanol, 10% v/v acetic acid solution 
followed by final destaining with 7% v/v acetic acid solution. The following standard 
proteins (BDH) was used as molecular mass markers: myoglobin (17,200), carbonic 
anhydrase (30,000), ovalbumin (42,700), albumin (66,250) and ovotransferrin 
(76,000-78,000) (Eumkeb, 1999).  
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CHAPTER IV 
RESULTS AND DISCUSSION 
  
4.1 Properties of bioactive compounds and yield from the pericarp   
       of Garcinia mangostana L. (GML) extract 
 Soxhlet extraction was chosen to extract the bioactive compounds from pericarp 
of G. mangostana L. fruit. Hexane, acetone, dichloromethane and ethanol were used 
as extractants due to their safety and free solubility of the compounds. Also, good 
efficiency of these solvents in degrading plant cell walls promotes a greater amount of 
endocellular material in the extract. The percent yield of CH2Cl2 crude extract, Fr3 
extract, and α-mangostin at 10.6 (106g), 0.235 (2.35g), and 0.0162 (0.01623g) % w/w 
of dried powder respectively were obtained. The purity of CH2Cl2 crude extract, Fr3 
extract, and α-mangostin was analyzed by HPLC and the structures of the compounds 
were identified by NMR spectra compare to the reference. 
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 4.1.1 Identification of bioactive compound present in the GML extract  
                  by HPLC 
 
Figure 4.1 HPLC chromatograms of standard α-mangostin obtained from Indofine 
chemical (A), Fr3 extract (B), CH2Cl2 crude extract (C) and α-mangostin 
extract (D). 
(A) 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
(C) 
 
 
 
 
 
 
(D) 
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  HPLC method with gradient elution was developed for the qualification of 
bioactive compounds from the pericarp of GML extract. The mixture of                             
0.2% formic acid in acetonitrile gave optimum chromatographic separation of                  
α-mangostin with other peaks in the extract (Figure 4.1). The wavelength at                 
240 nm was used for all measurements due to its maximum absorption. HPLC 
chromatograms of CH2Cl2 crude extract, Fr3 and α-mangostin extracted showed 
similar pattern with a major peak of α-mangostin at retention time of 5.333 min 
(Figure 4.1(A)), 5.289 min (Figure 4.1(B)), 5.276 min (Figure 4.1(C)) and 5.258 min 
(Figure 4.1(D)), respectively.  The identity of the peak of α-mangostin in the sample 
chromatograms was confirmed by spiking with the standard α-mangostin obtained 
from Indofine chemical company (Figure 4.1(A)). 
  HPLC method can be used for quantitative determination of α-mangostin 
in the extract from G. mangostana (Yodhnu et al., 2009). In addition, HPLC method 
was proven to be precise, specific, sensitive, and accurate for routine quantity 
assessment of raw material of mangosteen fruit rind, its extract, and products 
(Pothitirat et al., 2009). 
 4.1.2 Structural elucidation of α-mangostin from NMR 
  This compound, α-mangostin, is yellow a powder classified in the 
xanthone group. The structure contains two double bonds susceptible to 
hydrogenation, one methoxyl group and three hydroxyl groups as shown in Figure 4.2, 
Table 4.1, and 4.2 show
 1
H NMR and 
13
C NMR data of α-mangostin extracted 
compared to the reference. 
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Figure 4.2 Structure of α-mangostin from NMR chromatogram reported by Ee et al. 
(2006). 
 
Table 4.1 The 300 MHz 
1
H NMR (acetone-d6) spectral data of α-mangostin. 
Chemical Shift 
(δ, ppm) 
Assignment 
Chemical Shift (δ, ppm) 
from reference (Ee et al., 2006) 
13.78 singlet, OH-1 13.72 
6.82 singlet, H-5 6.72 
6.40 singlet, H-4 6.25 
5.27 triplet, H-12, H-17 5.26 
4.13 doublet, H-11 4.10 
3.80 singlet, 7-OMe 3.78 
3.35 doublet, H-16 3.37 
2.07 singlet, H-20 1.83 
2.05 singlet, H-15 1.82 
1.81 singlet, H-14 1.71 
1.65 singlet, H-19 1.68 
O
O OH
OHHO
H3CO
1
2
3
4
4a
10a
5
6
7
8
11
8a
9
9a
16
17
18
19
20
12
13
1514 
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    Figure 4.3 
1
H NMR spectroscopic data of α-mangostin extracted.  
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Table 4.2 The 300 MHz 
13
C NMR (acetone-d6), spectral data of α-mangostin. 
Chemical Shift 
(δ, ppm) 
Assignment 
Chemical Shift (δ, ppm) 
from reference (Ee et al., 2006) 
182.81 C-9 181.8 
162.92 C-3 161.6 
161.40 C-1 160.2 
157.39 C-6 155.4 
156.23 C-10a 155.2 
155.65 C-4a 154.8 
144.51 C-7 142.7 
138.14 C-8 137.2 
131.39 C-13 131.7 
124.82 C-17 123.4 
123.50 C-12 122.1 
112.06 C-8a 111.7 
111.00 C-2 109.7 
103.63 C-9a 103.1 
102.67 C-5 101.6 
93.15 C-4 92.4 
61.31 7-OCH3 61.2 
26.89 C-11 26.3 
25.92 C-14 25.7 
25.88 C-19 20.7 
22.00 C-16 21.3 
18.29 C-20 18.1 
17.90 C-15 17.7 
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                Figure 4.4 
13
C NMR spectroscopic data of α-mangostin extracted. 
 
4.2 Bacterial suspensions viable count absorption standard curve 
     The results of the bacterial suspensions viable count standard curve for oxacillin-
resistant Staphylococcus saprophyticus DMST 27055 (ORSS), ceftazidime–resistant 
Escherichia coli DMST 19629 (CREC), ceftazidime-resistant Enterobacter cloacae 
DMST 21394 (CREnC), oxacillin-sensitive Staphylococcus aureus ATCC 29213 
(OSSA) and  ceftazidime-sensitive  Escherichia  coli. ATCC 25922 (CSEC) are 
shown in Figures 4.5 to 4.9. 
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 Figures 4.5 to 4.9 indicate that approximately 1Х108 CFU/mL of ORSS, CREC, 
CREnC, OSSA, and CSEC have absorption at 500 nm of 0.19, 0.15, 0.14, 0.12, and 
0.10 respectively. This method was performed to count the exact bacterial number. 
 
Absorption of bacterial suspension viable count 
standard curve of S. saprophyticus DMST 27055 
Absorption at 500 nm.
.05 .10 .15 .20 .25 .30 .35 .40
cf
u
/m
l
107
108
109
 
 
Figure 4.5 Standard curves for suspensions of oxacillin-resistant Staphylococcus 
saprophyticus  DMST 27055. 
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Absorption of bacterial suspension viable count 
standard curve of E. coli DMST19629
Absorption at 500 nm.
.05 .10 .15 .20 .25
cf
u
/m
l
107
108
109
 
 
Figure 4.6   Standard curves for suspensions of ceftazidime-resistant Escherichia coli 
DMST 19629. 
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Absorption of bacterial suspension viable count 
standard curve of E. cloacae DMST 21394
Absorption at 500 nm.
.05 .10 .15 .20 .25
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u
/m
l
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Figure 4.7 Standard curves for suspensions of ceftazidime-resistant Enterobacter 
cloacae  DMST 21394. 
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Absorption of bacterial suspension viable count 
standard curve of S.aureus ATCC 29213
Absorption at 500 nm.
.05 .10 .15 .20 .25
cf
u
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Figure 4.8 Standard curves for suspensions of oxacillin-sensitive Staphylococcus 
aureus ATCC 29213. 
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Absorption of bacterial suspension viable count 
standard curve of E.coli ATCC 25922
Absorption at 500 nm.
.05 .10 .15 .20 .25
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u
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Figure 4.9 Standard curves for suspensions of ceftazidime-sensitive Escherichia  coli 
ATCC 25922. 
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4.3 MIC determination 
Table 4.3 Minimum inhibitory concentration of the following β-lactams and bioactive compounds from the pericarp of GML  extract 
against clinical isolates of oxacillin-resistant S. saprophyticus, ceftazidime-resistant E. coli, ceftazidime- resistant E. cloacae, 
oxacillin-sensitive S.  aureus and ceftazidime-sensitive E. coli  determined by agar dilution method.  
Bioactive 
compounds 
(µg/mL) 
Susceptibility (MIC) 
S. saprophyticus 
DMST 
27055 
S. aureus 
ATCC 29213 
(sensitive 
strian) 
E. coli 
DMST 19629 
E. coli 
ATCC 
25922 
(sensitive strian) 
E. cloacae 
DMST 21394 
E. coli 
ATCC 25922 
(sensitive strian) 
Crude extract 
(CH2Cl2) 
 
50 20 >10,000 >10,000 >10,000 >10,000 
Fr3 
 
31 7 >10,000 >10,000 >10,000 >10,000 
α-mangostin 
 
8 4 >1,024 >1,024 >1,024 >1,024 
Ceftazidime 
 
- - >1,024 8 >1,024 8 
Oxacillin 
 
128 2 - - - - 
6
3
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 These results showed MIC values of bioactive compounds from the pericarp of 
GML extract and selected drugs against clinical isolates of oxacillin-resistant              
S. saprophyticus, ceftazidime–resistant E. coli, ceftazidime-resistant E. cloacae, 
oxacillin-sensitive S. aureus and ceftazidime-sensitive E. coli determined by agar 
dilution method. Oxacillin alone showed some antibacterial activities against clinical 
isolates of oxacillin-resistant S. saprophyticus and clinical isolates of oxacillin-
sensitive S. aureus at MICs 128 and 2 μg/mL, respectively. The MIC of oxacillin 
against OSSA strain exhibited sensitive value (CLSI, 2013). Ceftazidime alone 
showed some antibacterial activities against clinical isolates of ceftazidime–resistant  
E. coli, clinical isolates of ceftazidime–resistant E. cloacae and clinical isolates of 
ceftazidime-sensitive E. coli  at  MICs  >1024, >1024 and 8 μg/mL, respectively. In 
the same way, the sensitive MIC value of ceftazidime against CSEC strain was proved 
(CLSI, 2013).   
 The MIC values of CH2Cl2 crude extract, Fr3 extract, and α-mangostin  against 
clinical isolates of oxacillin-resistant S. saprophyticus were 50, 31 and 8 µg/mL, 
respectively. Whereas, the MIC values of  CH2Cl2 crude extract, Fr3 extract, and α-
mangostin against both clinical isolates of ceftazidime-resistant E. coli and                
ceftazidime-resistant E. cloacae were at >10,000, >10,000 and >1,024  µg/mL, 
respectively. These MICs values against these sensitive strains were the same as those 
of resistant strains.   
These results indicate that bioactive compounds from the pericarp of GML 
extract exhibit higher potency against ORSS than oxacillin alone. On the other hand, 
the ceftazidime and bioactive compounds from the pericarp of GML extract did not  
inhibit  those of selected gram-negative bacteria. The results seem inconsistent with 
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those of Iikubo et al. (2002) that this extract showed antibacterial activity against 
Helicobacter pylori, which is a gram negative rod. Nevertheless, these results are in 
substantial agreement with those of Chomnawang et al. (2009) and Iinuma et al. 
(1996) that this extract inhibited MRSA, Staphylococcus epidermidis and 
Propionibacterium strain.  
In general, gram-negative drug-resistant bacteria were greater resistant to       
β-lactam antibiotics. These were likely to be the result of the difference in cell wall 
structure between gram-positive and gram-negative bacteria. The gram-negative 
bacteria has a multi-layered and complex structure. The outer membrane can act as a 
barrier to many environmental substances including antibiotics (Eumkeb et al., 2004). 
 
4.4 Checkerboard determination 
 The reasons to support the use of antimicrobial combinations are first the 
decreased emergence of resistant strains, secondly the decreased dose-related toxicity 
as a result of reduced dosage, and thirdly, polymicrobial infection (Lorian, 1999). 
Some previous researchers reported antibacterial activities of plant material 
combination with antibiotics against both gram-positive and gram-negative bacteria 
(Darwish et al., 2002; Liu et al., 2000). The oxacillin-resistant S. saprophyticus 
DMST 27055 was chosen to perform this method and crude extract, fraction 3, -
mangostin against oxacillin were investigated for synergistic effects. The 
isobolograms obtained from plotting of checkerboard MIC determination are shown in 
Figure 4.6 to 4.8. A summary of data from the isobolograms is given in Table 4.4. 
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Figure 4.10 Isobologram constructed from checkerboard MIC data showing    
antibacterial combination of oxacillin plus CH2Cl2 crude extract against 
clinical isolates of oxacillin-resistant S. saprophyticus DMST 27055. 
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  Figure 4.11 Isobologram constructed from checkerboard MIC data showing    
antibacterial combination of oxacillin plus Fr3 extract against clinical 
isolates of oxacillin-resistant S. saprophyticus DMST 27055. 
 
 
 
 
 
 
 
 
 
 
 
 
68 
oxacillin (g/ml)
0124 8 16 32 64 128

-m
an
g
o
st
in
 (

g
/m
l)
8
4
2
1
0
 
 
Figure 4.12 Isobologram constructed from checkerboard MIC data showing 
antibacterial combination of oxacillin plus α-mangostin against clinical 
isolates of oxacillin-resistant S. saprophyticus DMST 27055. 
 
Figure 4.10 to 4.12 indicate the synergistic activity for combinations of 
bioactive compounds from the pericarp of GML extract and oxacillin against clinical 
isolates of oxacillin-resistant S. saprophyticus DMST 27055 (FIC ≤ 0.5) (Johnson et 
al., 2004; Odds, 2003). The MICs of CH2Cl2 crude extract, Fr3 extract, and α-
mangostin plus oxacillin were reduced from 50, 31 and 8 μg/mL plus 128 μg/mL to 
6.25 (1/8 MIC), 3.875 (1/8 MIC) and 2 (1/4 MIC) μg/mL plus 16 (1/8 MIC) μg/mL, 
respectively, against this strain.  
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          The checkerboard results are shown in Tables 4.4. The synergistic activity for 
combination of bioactive compounds from the pericarp of GML extract and tested     
β-lactams against clinical isolates of oxacillin-resistant S. saprophyticus, ceftazidime-
resistant E. coli and ceftazidime-resistant E. cloacae were evaluated. The lowest 
fractional inhibitory concentration (FIC) for each combination was calculated as 
described in Chapter III. 
  
Table 4.4 Summary of the FICs for checkerboard assay of β-lactams used alone and in 
combination with bioactive compounds from the pericarp of GML extract 
against the drug resistant bacteria. 
Test 
bacteria 
Combination 
of agents 
MIC 
(µg/mL) 
MIC 
(A+B) 
FIC 
index 
value 
FIC 
index 
 
S. saprophyticus Oxacillin  
Crude extract  
128   
50 
16                  
6.25   
0.25 synergism 
Oxacillin                   
Fr3 
128   
31   
16                  
3.875  
0.138 synergism 
Oxacillin  
α-mangostin 
128   
8   
16                  
2  
0.375 synergism 
E. coli Ceftazidime 
Crude extract  
>1,024  
>10,000   
>1,024  
>10,000   
>2 no interaction 
or antagonism 
Ceftazidime  
Fr3 
>1,024  
>10,000   
>1,024  
>10,000   
>2 no interaction 
or antagonism 
Ceftazidime  
α-mangostin 
>1,024  
>1,024   
>1,024  
>1,024   
>2 no interaction 
or antagonism 
E. cloacae Ceftazidime 
Crude extract 
>1,024  
>10,000   
>1,024  
>10,000   
>2 no interaction 
or antagonism 
Ceftazidime  
Fr3 
>1,024  
>10,000   
>1,024  
>10,000   
>2 no interaction 
or antagonism 
Ceftazidime α-
mangostin 
>1,024  
>1,024  
>1,024  
>1,024  
>2 no interaction 
or antagonism 
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The checkerboard determinations demonstrated that the FICs index of 
CH2Cl2 crude extract, Fr3 and α-mangostin plus oxacillin exhibited synergistic effects 
at 0.25, 0.138 and 0.375 respectively. In general, these results indicate a high level 
synergistic activities since values below 0.5 are widely accepted as representing 
synergism between two antibacterials (American Society for Microbiology, 2004; 
Johnson et al., 2004; Odds, 2003). These results are consistent with earlier finding that 
synergism between alpha-mangostin plus gentamicin (GM) against vancomycin 
resistant Enterococci (VRE) , alpha-mangostin and vancomycin hydrochloride (VCM) 
against methicillin resistant Staphylococcus aureus (MRSA) were revealed (Sakagami 
et al., 2005). Furthermore, these results are in substantial agreement with those of 
(Eumkeb et al., 2010) that the combination of ceftazidime at 5 g/mL and 5 g/mL of 
test flavonoids (galangin, quercetin, and baicalein) exhibited synergistic effect by 
reduceing the CFU/mL of MRSA strain to 1 x 10
3
 over 6 and throughout 24h. These 
results indicate that bioactive compounds from the pericarp of GML extract not only 
have weak activity of  their own against ORSS but also have the ability to reverse the 
resistance of such bacterial strains to the activity of the primary antibiotics (Eumkeb et 
al., 2010).  
 
4.5 Killing curve determinations 
 Viable counts for the determination of the killing curves were performed  as 
previously described by Richards and Xing (1996) with  little modifications (Eumkeb, 
1999). 
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Figure 4.13 The effect of oxacillin combined with bioactive compounds from the 
pericarp of GML extract on the clinical isolates of oxacillin-resistant      
S. saprophyticus  DMST 27055.  The values plotted are the means of      
3 observations, and the vertical bars indicate the standard errors of the 
means.   
 
Sampling killing curves resulting from CH2Cl2 crude extract, Fr3 and                      
α-mangostin alone and in combination with oxacillin against clinical isolates of 
oxacillin-resistant S. saprophyticus  are presented in Figure 4.13. The control showed 
no reduction in the counts of CFU from control inoculum. The results showed that the 
combination of CH2Cl2 crude extract (3.125 μg/mL) plus oxacillin (8 μg/mL),                
Fr3 (1.94 μg/mL) plus oxacillin (8 μg/mL) and α-mangostin (1 μg/mL) plus oxacillin 
(8 μg/mL) caused a reduction of 5 x 105 CFU/mL of clinical isolates of oxacillin-
resistant S. saprophyticus DMST 27055 to 10
3
 CFU/mL within 6 h and throughout the 
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remainder of a 24 h period. These results seem consistent with earlier findings that 
Ceftazidime at 5 g/mL in combination with 5 g/mL of tested flavonoids reduced the 
CFU/mL of MRSA strain by 5 x 10
3
 over 6 h. The reduced counts did not recover 
within   24 h (Eumkeb et al., 2010).  
These results provide evidence that bioactive compounds from the pericarp of 
GML extract (CH2Cl2 crude extract, Fr3 extract, and α-mangostin) in combination with 
oxacillin have synergistic activity against clinical isolates of oxacillin-resistant           
S. saprophyticus. In fact, the results of checkerboard assay, synergistic effects, are 
confirmed by this finding. 
 
4.6 Transmission electronmicroscopy (TEM) 
 Electronmicroscope investigations clearly showed that the combination of 
oxacillin with  bioactive compounds from the pericarp of GML extract caused damage 
to ultrastructures of  clinical isolates of oxacillin-resistant  S. saprophyticus  (Figures 
4.14-4.21). 
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(a) 
 
 
 
(b) 
 
 
Figure 4.14 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), control 
(no antibacterial agent). x4,000, bar = 1 μm (a); x15,000, bar = 500 nm 
(b). 
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(a) 
 
(b) 
Figure 4.15 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), 
oxacillin (32 μg/mL). x4,000,  bar = 1 μm (a); x19,500, bar = 200 nm (b). 
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(a) 
 
(b) 
 
Figure 4.16 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), crude 
extract (6.25 µg/mL). x4,000,  bar = 1 μm (a); x29,000, bar = 200 nm 
(b). 
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(a) 
 
(b) 
 
Figure 4.17 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), Fr3 
(2.50 µg/mL). x5,000,  bar = 1 μm (a); x15,000, bar = 500 nm (b). 
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(a) 
 
(b) 
 
Figure 4.18 Utrathin sections of log phase of clinical isolates of oxacillin-resistant      
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b),            
α-mangostin (1.2 μg/mL). x9,900,  bar = 500 nm (a); x29,000, bar = 200 
nm (b) 
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(a) 
 
(b) 
 
Figure 4.19 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), 
oxacillin (8 μg/mL) plus crude extract (3.125 µg/mL). x4,000,  bar = 1 
μm (a); x9,900, bar = 500 nm (b). 
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(a) 
 
(b) 
 
Figure 4.20 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus  grown for 4 h in Mueller-Hinton broth: (a), (b), 
oxacillin (8 μg/mL) plus  Fr3 (1.938  µg/mL). x4,000, bar = 1 μm (a); 
x19,500, bar = 200 nm (b). 
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(a) 
 
(b) 
Figure 4.21 Utrathin sections of log phase of clinical isolates of oxacillin-resistant     
S. saprophyticus grown for 4 h in Mueller-Hinton broth: (a), (b), 
oxacillin (8 μg/mL) plus α-mangostin (1 μg/mL). x5,000, bar = 1 μm 
(a); x29,000, bar = 200 nm (b). 
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 Figure 4.14 shows the appearance of normal log phase cells of clinical isolates 
of oxacillin-resistant S. saprophyticus. The cell wall and cytoplasmic membrane can 
be distinguished.  
Figure 4.15 shows the effect of 32 µg/mL oxacillin on clinical isolates of 
oxacillin-resistant S. saprophyticus strain. Tested antibiotics showed no activity 
against the clinical isolates of oxacillin-resistant S. saprophyticus. These treated cell 
sizes seemed slightly smaller than those of control cell sizes.  
Figure 4.16 shows the micrographs of log phase cells of clinical isolates of 
oxacillin-resistant S. saprophyticus after treatment with crude extract at 6.25 µg/mL. 
The crude extract treated cells showed rather smaller than those of normal cells. Most 
of these bacteria exhibited cell membrane damage. 
Figure 4.17 shows the micrographs of log phase cells of clinical isolates of 
oxacillin-resistant S. saprophyticus after treatment with Fr3 extract at 2.50 µg/mL. 
These treated cells were considerably smaller than those of control cells. Most of these 
bacteria exhibited cell membrane and morphological damage. 
Figure 4.18 shows the micrographs of log phase cells of clinical isolates of 
oxacillin-resistant S. saprophyticus after treatment with α-mangostin at 1.2 μg/mL. 
The majority of these cells were substantially smaller than the control cells. Many of 
these bacteria exhibited change in morphology and cell membrane damage. 
Figure 4.19 shows the effect of the combination of oxacillin 8 μg/mL plus 
crude extract 3.125 µg/mL on clinical isolates of oxacillin-resistant S. saprophyticus. 
The majority of these cells were rather smaller than the control cells. Some of these 
cells showed cell shape distortion and cell membrane damage. 
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Figure 4.20 shows the effect of the combination of oxacillin 8 μg/mL plus Fr3 
extract 1.938 µg/mL on clinical isolates of oxacillin-resistant S. saprophyticus. Most 
of these cells revealed cell shape distortion and cell membrane damage. 
Figure 4.21 shows the effect of the combination of oxacillin 8 μg/mL plus α-
mangostin 1  μg/mL on clinical isolates of oxacillin-resistant S. saprophyticus. Most 
of these cells showed a great deal smaller than the control cells. The majority of these 
cells undoubtedly exhibited cell shape and cell membrane. 
These results are consistent with those of Eumkeb et al. (2010) that 
electronmicroscopy clearly showed that the combination of galangin and ceftazidime 
caused damage to the ultrastructures of the cells of MRSA strain.  Apart from this, 
these results are in correspondence with those of (Oonmetta-aree et al., 2006) that 
transmission electron microscopy clearly demonstrated that galangal extract caused 
both outer and inner membrane damage and cytoplasm coagulation of S. aureus strain.   
From these results, it can be concluded that the oxacillin had little activity against 
clinical isolates of oxacillin-resistant S. saprophyticus. Whereas, biochemical 
compounds of GML extracts showed much higher potency than oxacillin against this 
strain. Moreover, the combination of oxacillin and these bioactive compounds 
obviously showed great synergism activity against this strain, as supported in Figure 
4.21.  
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4.7 Outer membrane (OM) permeability 
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Figure 4.22 Permeabilization of clinical isolates of oxacillin-resistant S. saprophyticus  
by bioactive compounds from the pericarp of GML extract alone and in 
combination with oxacillin and lysis caused by subsequent treatment 
with 300 μg/mL  TTX-100. The bars represent the standard deviations of        
3 replicates.  
 
 Figure 4.22  shows  the OM permeabilization of clinical isolates of oxacillin-
resistant  S. saprophyticus  by oxacillin,  CH2Cl2 crude extract, Fr3 extract, and          
α-mangostin at concentrations of 32 μg/mL, 6.25 μg/mL, 2.50 μg/mL and 1.2 μg/mL, 
respectively, alone  and  in combination of oxacillin 8 μg/mL plus CH2Cl2 crude 
extract 3.125 μg/mL, oxacillin 8 μg/mL plus Fr3 1.94 μg/mL and oxacillin 8 μg/mL 
plus α-mangostin 1 μg/mL. These results revealed that bioactive compounds from the 
pericarp of GML extract (CH2Cl2 crude extract, Fr3 extract, and α-mangostin) and 
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oxacillin altered the OM permeability of clinical isolates of oxacillin-resistant            
S. saprophyticus when they were used alone and in combination at above 
concentrations. Triton X-100 was used as permeabilizing probe. These results are 
consistent with previous findings that D,L-1’-Acetoxychavicol acetate caused S. 
aureus outer membrane damage (Oonmetta-aree et al., 2006). Besides, the 
combination of both galangal extract plus amoxicillin and luteolin plus amoxicillin or 
apigenin plus ceftazidime also caused OM altered permeabilization of amoxicillin 
resistant E. coli or ceftazidime resistant E. cloacae respectively (Eumkeb and 
Chukrathok, 2013; Eumkeb et al., 2011; Eumkeb et al., 2012).  These findings 
indicate that OM permeability alteration this strain by either these bioactive 
compounds from the pericarp of GML extracts alone or in combination with oxacillin 
may play one of several important mechanism of actions and leads to cell lysis. 
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4.8  Cytoplasmic membrane (CM) permeability  
Table 4.5 β-galactosidase activity results of clinical isolates of oxacillin-resistant S. saprophyticus  after treatment with bioactive 
compounds from the pericarp of GML extract  used alone and in combination with oxacillin 1 = Control, 2 = oxacillin     
32 μg/mL, 3 = α-mangostin 1.2 μg/mL, 4 = Fr3 2.50 μg/mL, 5 = crude extract 6.25 μg/mL, 6 = oxacillin 8 μg/mL plus  α-
mangostin 1 μg/mL, 7 = oxacillin 8 μg/mL plus Fr3 1.94 μg/mL and 8 = oxacillin 8 μg/mL plus crude extract 3.125 μg/mL. 
Time 1 2 3 4 5 6 7 8 
Positive  control 
Toluene 50 
µL/mL 
A420 
0 h Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg 
1 h Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg 
2 h Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg 
3 h Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg 
4 h Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 
5 h Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos 
 Neg = No evidence of activity, Pos= have evidence of activity 
 
8
5
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 The effect of either oxacillin and bioactive compounds from the pericarp of 
GML extract alone or in combination on the cytoplasmic membrane permeabilization 
of clinical isolates of oxacillin-resistant S. saprophyticus was investigated using the 
cytoplasmic enzyme β-galactosidase. The results showed that there was no increase in 
β-galactosidase activity with increasing time in the presence of either these agents 
alone or in combination within 0-3 h period. These finding suggest that it is likely that 
these compounds increase the permeability of the cytoplasmic membrane of S. 
saprophyticus after 4 h of treatment. In the same way, these results are consistent with 
previous findings that D,L-1’-Acetoxychavicol acetate caused S. aureus CM damage. 
Then, the cytoplasmic membranes impermeability properties was disrupted by 
determining the release of cell materials including nucleic acid which absorbed at 260 
nm (Oonmetta-aree et al., 2006). In addition, the combination of luteolin plus 
amoxicillin or apigenin plus ceftazidime also caused CM altered permeabilization of 
amoxicillin resistant  E. coli or ceftazidime resistant E. cloacae respectively (Eumkeb 
and Chukrathok, 2013; Eumkeb et al., 2012).  
 These results can be explained by assuming that the cytoplasmic membrane is 
also a highly selective barrier, enabling a cell to concentrate specific metabolites and 
excrete waste materials. The general structure of most biological membranes is a 
phospholipid bilayer. The major proteins of the cell membrane generally have very 
hydrophobic external surface in the regions of the protein that make intimate 
association with the highly non-polar fatty acid chains (Brock et al., 1997; Tropp, 
1997).  
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4.9 Electrophoresis 
The result of SDS-PAGE is shown in Figure 4.23. 
 
 
 
Figure 4.23 SDS-PAGE showing the bacterial membrane and peptidoglycan 
associated protein (BMPG) of  clinical isolates of oxacillin-resistant  
S. saprophyticus DMST 27055 grown in the absence of drug (contron; 
lane 1), oxacillin 32 μg/mL (lane 2), α-mangostin 1.2 μg/mL (lane 3), 
Fr3 2.50 μg/mL (lane 4), crude extract 6.25 μg/mL (lane 5), oxacillin 8 
μg/mL plus α-mangostin 1 μg/mL (lane 6), oxacillin 8 μg/mL plus Fr3 
1.94 μg/mL (lane 7), oxacillin 8 μg/mL plus crude extract 3.125 
μg/mL (lane 8), BSA; standard Bovine serum and std;  molecular 
weight marker proteins (kDa). 
1     2     3     4     5     6     7     8     BSA     std 
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   Figure 4.23 shows that SDS-PAGE exhibited the BMPG of  clinical isolates of 
oxacillin-resistant  S. saprophyticus  grown in the absence of drug (control; lane 1) 
and presence of bioactive compounds from the pericarp of GML extract; oxacillin 
alone at 32 μg/mL (lane 2), α-mangostin alone at 1.2 μg/mL (lane 3), Fr3 extract  alone 
at 2.50 μg/mL (lane 4), crude extract alone at 6.25 μg/mL (lane 5), oxacillin 8 μg/mL 
plus α-mangostin 1 μg/mL (lane 6), oxacillin 8 μg/mL plus Fr3 extract 1.94 μg/mL 
(lane 7), and oxacillin 8 μg/mL plus crude extract 3.125 μg/mL (lane 8). Bovine serum 
albumin (BSA) was used as protein standard. Protein in  kDa is represented for 
molecular weight marker protein. 
 The BM-PG associated protein bands of clinical isolates of oxacillin-resistant 
S. saprophyticus after treatment with bioactive compounds from the pericarp of GML 
extract are shown in Figure 4.23. It is noticed that there was an absence of protein 
band at MW 75, 100, 150 and 250 kDa of lane 2 to lane 8 of treated cells compared to 
control. On the contrary, the BMPG band of treated cells appeared darker than the 
control at MW 25 kDa. These findings lend support to the assumption that higher MW 
proteins of these treated cells were disrupted. Therefore, lower MW proteins were 
established. Thus, the BMPG associated protein synthesis may be disrupted by these 
GML extracts.   
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CHAPTER V 
CONCLUSIONS 
 
 The emergence of multidrug resistance in pathogenic bacteria has increased. 
Thus, the search for new antibiotics and new approaches to treat these bacterial 
infections are urgently needed. Staphylococcal resistance to a wide spectrum of β-
lactam antibiotics, such as  methicillin, oxacillin and flucloxacillin, began to emerge 
soon  after the introduction of the first drug in this class,  and  there has been a steady 
risen in the incidence of methicillin  resistant S. aureus (MRSA) clinical isolates 
(Bush, 2004). An interesting source of novel therapeutics are plant-derived 
antibacterials, such as galangal from which there has been extracted on active 
ingredient called galangin which showed synergism with penicillin for MRSA 
inhibition (Eumkeb et al., 2010). The xanthones, α- and γ-mangostin, are major 
bioactive compounds found in the pericarp of the mangosteen. The biological 
activities of α-mangostin have been confirme in that it has antimicrobial activity 
against methicillin-resistant Staphylococcus aureus and Helicobacter pylori 
(Chomnawang et al., 2009; Iikubo et al., 2002; Iinuma et al., 1996). No works have 
been done on the effect of GML extract on drug resistant bacteria such as 
Staphylococcus saprophyticus (S. saprophyticus), Enterobacter cloacae (E. cloacae), 
and Escherichia coli (E. coli). The purpose of this study was to investigate the 
activity of a bioactive compound, -mangostin, from the pericarp extract of Garcinia 
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mangostana against these drug resistant bacteria, when used alone and in 
combination with β-lactam antibiotics. 
 The mature mangosteen fruits (Garcinia mangostana L.) were collected from 
Nakhon Ratchasima. The extraction and identification methods were accomplished. 
The CH2Cl2 crude extract, Fr3 extract, and α-Mangostin were extracted by Soxhlet 
extraction. The HPLC chromatograms of these extracts showed similar patterns with 
a major peak of α-mangostin at retention time around 5.33 min.  Then, the main 
compound structure was identified as -mangostin using NMR and compared with 
the reference.  The bacterial suspension standard curves of all tested strains were 
executed to count the exact bacterial numbers. The MIC values of CH2Cl2 crude 
extract, Fr3 extract, α-mangostin and oxacillin against clinical isolates of oxacillin-
resistant S. saprophyticus revealed 50, 31, 8 and 128 µg/mL, respectively. The MIC 
values of  CH2Cl2 crude extract, Fr3 extract, α-mangostin and ceftazidime against 
both clinical isolates of ceftazidime-resistant E. coli and ceftazidime-resistant E. 
cloacae strains showed at >10,000, >10,000, >1,024 and >1,024  µg/mL respectively. 
Thus, these results indicate that bioactive compounds from the pericarp of GML 
extract revealed a great deal higher potency against ORSS than oxacillin alone. The 
high resistance to ceftazidime and bioactive compound extracts from the pericarp of 
GML of both E. coli and E. cloacae strains were demonstrated. These results are 
concistent with those of Chomnawang et al. (2009) and Iinuma et al. (1996) that this 
extract inhibited MRSA, Staphylococcus epidermidis and Propionibacterium strains.   
These findings lend support to the assumption that these seem to be the result of the 
difference in cell wall structure between gram-positive and gram-negative bacteria. 
The gram-negative bacteria has a multi-layered and complex structure. The outer 
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membrane can act as a barrier to many environmental substances including 
antibiotics (Eumkeb et al., 2004).  
    The checkerboard results displayed that the MICs of CH2Cl2 crude extract, Fr3 
extract, and α-mangostin plus oxacillin were reduced from 50, 31 and 8 μg/mL plus 
128 μg/mL to 6.25 (1/8 MIC), 3.875 (1/8 MIC) and 2 (1/4 MIC) μg/mL plus 16              
(1/8 MIC) μg/mL, respectively, against ORSS strain. For this reason, the FICs index 
of CH2Cl2 crude extract, Fr3 and α-mangostin plus oxacillin revealed synergistic 
effects at 0.25, 0.138 and 0.375 respectively against ORSS strain. 
 These results are in substantial agreement with earlier findings that synergism 
between alpha-mangostin plus gentamicin (GM) against vancomycin resistant 
Enterococci (VRE), alpha-mangostin and vancomycin hydrochloride (VCM) against 
methicillin resistant Staphylococcus aureus (MRSA) were recorded (Sakagami et al., 
2005). These results suggest that these compounds from the pericarp of GML extract 
not only have weak activity of their own against ORSS but also have the ability to 
reverse the resistance of such bacterial strain to the activity of the primary antibiotics 
(Eumkeb et al., 2010).  
 The killing curves proved that the combination of CH2Cl2 crude extract (3.125 
μg/mL), Fr3 (1.94 μg/mL) and  α-mangostin (1 μg/mL) each plus oxacillin (8 μg/mL) 
caused a marked decrease of 5 x 10
5
 CFU/mL of ORSS to 10
3
 CFU/mL within 6 h 
and throughout the remainder of a 24 h period. These results imply that these 
bioactive compounds in combination with oxacillin have synergistic activity against 
this strain. In fact, the results of checkerboard assay, as synergistic effects, are 
confirmed by this finding.  
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     Furthermore, the TEM method exhibited that the effect of the combination of 
oxacillin plus these compound from GML extracts including α-mangostin at sub-MIC 
value on ORSS revealed great deal smaller than the control cells. The majority of 
these cells undoubtedly exhibited cell shape distortion and cell envelope damage in 
most of these cells. These results are in substantial agreement with those of Eumkeb 
et al. (2010) that electronmicroscopy clearly exhibited the combination of galangin 
and ceftazidime caused damage to the ultrastructures of the cells of MRSA strain. 
These findings lend support to the assumption that either these GML extracts alone or 
in combination with oxacillin may inhibit cell wall synthesis leads to cell shape 
distortion and cell envelope damage.  
     In addition, the OM permeabilization results demonstrated that either bioactive 
compounds from this plant including α-mangostin alone or in combination with 
oxacillin at sub MIC value slow increased the OM permeability of ORSS strain. 
These results are correspondence with previous findings that D,L-1’-Acetoxychavicol 
acetate caused S. aureus outer membrane damage (Oonmetta-aree et al., 2006).  
     In the same way, the cytoplasmic membrane permeabilization results showed 
that there was no increase in β-galactosidase activity with increasing time in the 
presence of either bioactive compounds from this plant including α-mangostin alone 
or in combination with oxacillin at sub MIC value within 0-3 h whereas exhibited this 
enzyme positive activity from 4-5 h periods.  These finding provide evidence that it is 
likely that these compounds markedly increase the permeability of the cytoplasmic 
membrane of ORSS strain after 4 h of treatment. These results are consistent with 
previous findings that D,L-1’-Acetoxychavicol acetate caused S. aureus CM damage 
(Oonmetta-aree et al., 2006). These results can be explained by assuming that the 
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cytoplasmic membrane is also a highly selective barrier, enabling a cell to 
concentrate specific metabolites and excrete waste materials. The general structure of 
most biological membrane is a phospholipid bilayer. Consequently, these extracts 
either alone or in combination with oxacillin take a long time to penetrate CM of this 
resistant strain.  
     Besides, the SDS-PAGE results exhibited that there was an absence of protein 
bands at MW 75, 100, 150 and 250 kDa of lane 2 to lane 8 of either bioactive 
compounds from this plant including α-mangostin alone or in combination with 
oxacillin at sub MIC value treated cells compared to control. Whereas, the BMPG 
band of these treated cells appeared darker than the control at MW 25 kDa.  These 
findings lend support to the assumption that higher MW proteins of these treated cells 
were disrupted. Therefore, lower MW proteins were established. So, the BMPG 
associated protein synthesis me be disrupted by these GML extracts. 
     From these results, it can be concluded that the oxacillin had little activity 
against clinical isolates of oxacillin-resistant S. saprophyticus. Whereas, biochemical 
compounds of GML extracts showed rather higher potency than oxacillin alone 
against this strain. Moreover, the combination of oxacillin and these bioactive 
compounds, especially -mangostin, obviously showed great synergic activity 
against this strain. So, our findings provide evidence that these plant extract 
compounds have the synergistic effect with oxacillin to reverse bacterial resistance to 
oxacillin against this resistant strain.  
     To conclude, this activity may be involved two mechanisms of action by these 
GML extract compounds in combination with oxacillin.  The first is on the cell wall 
(peptidoglycan) synthesis inhibition. The second mode of action is a steady increased 
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OM and CM permeabilization. These GML extract compounds including                           
-mangostin have a sufficient margin of safety for therapeutic use.  For this reason, 
these extract compounds offer for the development of a valuable adjunct to oxacillin 
against ORSS, which currently almost penicillins resistance. These in vitro results 
have to be still confirmed in an animal or in humans test. If possible, blood and tissue 
levels would be achievable to work synergistically.  
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